| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b interim results example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2b interim results example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2b interim results example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Veru Inc.$2.78
+0.03 (+1.06%)
D 37Pipeline Score Fair Value Pharma · Commercial
Market Cap
37.72 M
EPS
-0.81
P/E Ratio
-
Value Trade
159.74 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
3.15 M
Total Assets
43.08 M
Total Liabilities
8.30 M
Equity
34.79 M
D/E Ratio
12,345
12.44 %
Week
-2.49 %
1 Month
-5.62 %
3 Month
6.33 %
6 Month
-97.13 %
5 Year
-96.45 %
All Time
Cash Data
Cash Position
27.60 M
Monthly Burn
2.41 M
Runway
9.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
165.20 K
52 Week Range
2.05 - 7.40
% held by Insiders
12.84 %
% held by Institutions
22.53 %
Enterprise Value
9.79 M
Total Shares
16.04 M
Short %
5.01 %
Float Shares
13.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veru Inc.
846Total events
5Upcoming
194Tier-1 (high impact)
2010 – 2045Coverage
Upcoming catalysts 5
Event history 841
Jun 2026
▲Partnership / LicenseEnobosarmCorporate
Clinical supply agreement with Novo Nordisk for PLATEAU study
Obesitysource ↗
May 13, 2026
May 13, 2026
Mar 9, 2026
▲First Patient DosedEnobosarmTrial
First patient enrolled in Phase 2b PLATEAU trial of enobosarm + semaglutide for high quality weight loss
obesitysource ↗
Feb 26, 2026
◆Oral PresentationPresentation
Veru to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 11, 2026
Q1 2026
Dec 19, 2025
▲FDA Feedback ReceivedEnobosarmFDA Meeting
FDA announced total hip BMD as validated surrogate endpoint for osteoporosis drug development
osteoporosissource ↗
Dec 17, 2025
Dec 17, 2025
▼Equity OfferingCorporate
Completed public offering for net proceeds of approximately $23.4 million
Dec 13, 2025
◆Oral PresentationEnobosarmPresentation
Enobosarm presentation at SCWD 18th International Conference
sarcopenia, cachexia, wasting disorderssource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $39M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.0x
rNPV / MCap Top 51%
Micro Cap (rank 447 of 911)
Percentile RankVeru Inc. faces pipeline headwinds (37/100), with $1.7B risk-adjusted pipeline value, led by Enobosarm in Obesity & Overweight (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enobosarm Small molecule | Muscle Loss | Phase 2 | NCT06282458 | 23% | $1.1B | COMPLETED | 168 | - | - | Aug 22, 2025 | - | Sep 17, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
enobosarm | obesity | Phase 2b | 2026-02-19 | 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction Read More | Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
enobosarm | obesity | Phase 2b | 2026-02-19 | 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction Read More | Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More | |
enobosarm | obesity | Phase 2b | 2026-02-19 | 168 older patients (≥60 years of age) receiving semaglutide (Wegovy®) for weight reduction Read More | Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VERU
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VERU Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-14 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VERU▲ +1.1%today
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Veru Inc. will present at the 2026 Obesity & Weight Loss Drug Development Summit in Boston, focusing on innovative treatments for obesity. Key presentations include strategies for combating sarcopenic obesity in geriatric patients and advancing regulatory frameworks. The company is also conducting a Phase 2b clinical study to evaluate the efficacy of enobosarm combined with GLP-1 RA therapy.
Read more →VERUVeru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru Inc. reported its fiscal 2026 second quarter results, highlighting progress in the Phase 2b PLATEAU clinical trial for enobosarm combined with semaglutide. The trial is actively enrolling participants and is expected to conduct an interim analysis in early 2027. Financial results show a decrease in operating loss and net loss compared to the previous year.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATE
Veru Inc. reported its financial results for the second quarter of fiscal 2026 and updated on the progress of its Phase 2b PLATEAU clinical trial. The trial is evaluating the combination of enobosarm and semaglutide in older patients with obesity and is currently enrolling participants. The interim analysis is expected in the first quarter of 2027, following promising results from the previous Phase 2b QUALITY study. Veru continues to develop its novel drugs aimed at improving body composition and physical function for patients with cardiometabolic diseases.
Read more →VERUVeru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Veru Inc. will host a conference call on May 13, 2026, to discuss its fiscal 2026 second quarter financial results and provide a business update. The company is focused on developing innovative treatments for cardiometabolic and inflammatory diseases, including its late-stage drug enobosarm, which is being evaluated in clinical trials for obesity. The Phase 2b PLATEAU study aims to assess the drug's effectiveness in combination with semaglutide for weight loss.
Read more →VERUVeru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru Inc. has initiated the Phase 2b PLATEAU clinical trial, enrolling its first patient to evaluate the combination of enobosarm and semaglutide for weight loss in older patients with obesity. The trial aims to assess the preservation of lean mass and physical function while enhancing fat loss. Interim results are anticipated in early 2027, with final data expected by the end of that year.
Read more →VERUVeru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Veru Inc. announced that CEO Mitchell Steiner will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company is advancing its clinical programs, notably enobosarm, which has shown positive results in clinical trials targeting obesity and related health issues. Veru aims to conduct further studies, including a planned Phase 2b clinical trial to evaluate enobosarm's effectiveness alongside GLP-1 RA therapy. The detailed study design includes assessments of body composition, physical function, and safety, with enrollment expected to commence in early 2026.
Read more →VERUVeru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Veru Inc. reported its fiscal 2026 first quarter results, highlighting the upcoming Phase 2b PLATEAU trial for enobosarm in combination with semaglutide to address weight loss plateaus in older patients with obesity. The company noted positive outcomes from its previous Phase 2b QUALITY trial and received favorable FDA feedback regarding regulatory pathways for enobosarm. The trial is expected to commence this quarter, with interim results anticipated in early 2027.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Progra
Veru Inc. has reported its fiscal 2026 first quarter financial results, highlighting progress in its clinical programs. The company is set to initiate the Phase 2b PLATEAU clinical trial, which will evaluate the combination of enobosarm and semaglutide in older patients with obesity. Positive outcomes from the previous QUALITY trial bolster the case for this combination therapy, aimed at overcoming weight loss plateaus while preserving muscle mass. The FDA has provided guidance indicating potential regulatory pathways for approval, enhancing the company's developmental prospects.
Read more →VERU▼ -11.5%on this news
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Veru Inc. will host a conference call on February 11, 2026, to discuss its fiscal 2026 first quarter financial results and provide a business update. The company is focused on developing innovative treatments for cardiometabolic and inflammatory diseases, with ongoing clinical trials for its drugs enobosarm and sabizabulin. The Phase 2b PLATEAU clinical study is set to begin in early 2026, aiming to evaluate the efficacy of enobosarm in patients with obesity.
Read more →VERU▼ -8.6%on this news
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Veru Inc. reported its fiscal year 2025 financial results and highlighted progress in its clinical programs, particularly the enobosarm obesity treatment. Following positive results from the Phase 2b QUALITY study, the FDA has provided regulatory guidance, allowing for a focus on incremental weight loss as a primary endpoint. The company plans to initiate the Phase 2 PLATEAU study in Q1 2026 to further evaluate enobosarm's efficacy in older patients.
Read more →VERU▼ -8.6%on this newsshared move
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progres
Veru Inc. reported positive financial results for FY 2025 and announced progress in its clinical programs. Following favorable outcomes from the Phase 2b QUALITY study, the company has received FDA regulatory guidance for its treatment enobosarm in combination with GLP-1 RA for obesity. Veru plans to initiate the Phase 2 PLATEAU clinical study aimed at enhancing weight loss efficacy and preserving muscle mass, expected to start in Q1 2026. Additionally, the company completed a public offering to bolster its clinical development efforts.
Read more →VERUVeru to Report Fiscal Year 2025 Financial Results on December 17th
Veru Inc. will host a conference call on December 17, 2025, to discuss its fiscal year 2025 financial results and provide a business update. The company is focused on developing treatments for cardiometabolic and inflammatory diseases, with notable progress in its enobosarm and sabizabulin programs. The Phase 2b PLATEAU clinical study is set to evaluate enobosarm's efficacy in patients with obesity starting in Q1 2026.
Read more →VERUVeru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Veru Inc. announced its participation in the Society on Sarcopenia, Cachexia, and Wasting Disorders' 18th International Conference and Regulatory Workshop in Rome. CEO Mitchell Steiner will present on weight loss drugs and strategies to address sarcopenia. The company aims to highlight its innovative drug enobosarm, which targets obesity and muscle preservation.
Read more →VERUVeru to Present Two Abstracts at ObesityWeek 2025
Veru Inc. announced the presentation of two abstracts at ObesityWeek 2025 in Atlanta. The presentations will focus on the effects of enobosarm in combination with GLP-1 RA drugs for weight loss. The company aims to demonstrate how enobosarm can selectively reduce fat while preserving lean mass. This follows positive results from previous clinical studies.
Read more →VERU▼ -14%on this news· ran to -27% by day 3shared move
Veru Announces Pricing of $25 Million Public Offering
Veru Inc. has announced the pricing of a public offering aimed at raising $25 million. The offering includes common stock and various warrants, with a closing date expected around October 31, 2025. Proceeds will primarily fund the Phase 2b PLATEAU clinical study for enobosarm, along with general corporate purposes. The offering is contingent upon customary closing conditions.
Read more →VERU▼ -14%on this news· ran to -27% by day 3shared move
Veru Announces Proposed Public Offering
Veru Inc. has announced a proposed public offering of its common stock, which includes pre-funded warrants and accompanying Series A and B warrants. The proceeds from this offering will primarily fund the Phase 2b PLATEAU clinical study for enobosarm, along with general corporate purposes. The offering is subject to market conditions, and the final terms remain uncertain.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Announces Proposed Public Offering MIAMI, FL
Veru Inc. has announced it will commence an underwritten public offering of its common stock and associated warrants. The proceeds from this offering are primarily intended to support the development of its candidate enobosarm, particularly for the Phase 2b PLATEAU clinical study. However, the offering is dependent on market conditions, leading to uncertainties regarding its completion and terms. This move, while a strategic step toward advancing their pipeline, comes with potential risks and unknowns that could affect the company's future.
Read more →VERU▼ -5.6%on this news
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
Veru Inc. has announced a successful meeting with the FDA, which provided regulatory clarity for enobosarm as a muscle preservation drug in combination with GLP-1 RA for obesity treatment. The FDA now accepts incremental weight loss as a primary endpoint for approval. Veru plans to advance enobosarm into a Phase 2b trial to assess its efficacy in older and younger patients with obesity.
Read more →VERU▼ -11.7%on this news
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
Veru Inc. reported positive results from its Phase 2b QUALITY study, demonstrating that enobosarm, when added to semaglutide, preserves muscle and promotes fat loss. The company also shared findings from the Maintenance Extension study, indicating enobosarm's effectiveness in preventing weight regain. A novel modified release formulation of enobosarm has been selected for future clinical studies, with FDA feedback anticipated.
Read more →VERU▼ -11.7%on this newsshared move
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Progra
Veru Inc. has announced its fiscal 2025 third quarter financial results along with clinical progress on enobosarm, a drug aimed at weight management. The company reported positive outcomes from the Phase 2b QUALITY study, which indicated that enobosarm, when used with semaglutide, preserves muscle and promotes fat loss more effectively than semaglutide alone. Additionally, a new modified release oral formulation of enobosarm was selected based on favorable pharmacokinetic results. The company looks forward to FDA feedback regarding the regulatory pathway for enobosarm as a treatment option for maintaining lean mass during weight loss.
Read more →VERUVeru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
Veru Inc. has selected a novel modified release oral formulation of enobosarm for chronic weight loss management after confirming pharmacokinetic endpoints in a clinical study. The formulation demonstrated a distinct release profile and is protected by a robust patent estate. Positive results from previous Phase 2b studies support its efficacy, with plans for Phase 3 studies underway.
Read more →VERU▼ -18.7%on this newsshared move
Veru Announces Reverse Stock Split
Veru Inc. has announced a 1-for-10 reverse stock split effective August 8, 2025, to regain compliance with Nasdaq's minimum bid price requirement. This action was approved by shareholders and aims to stabilize the company's stock price. All outstanding stock options and equity plans will be proportionally affected, with no fractional shares issued.
Read more →VERU▼ -6.4%on this news· ran to -24% by day 1shared move
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
Veru Inc. will host a conference call on August 12, 2025, to discuss its fiscal 2025 third quarter financial results and provide a business update. The company has reported positive outcomes from its Phase 2b QUALITY clinical study of enobosarm, which is aimed at improving body composition in patients. The results indicate that enobosarm effectively prevents weight and fat regain after discontinuation of semaglutide treatment.
Read more →VERUVeru to Participate in the 2025 BTIG Virtual Biotech Conference
Veru Inc. announced its participation in the 2025 BTIG Virtual Biotech Conference, scheduled for July 29-30, 2025. The company will engage in one-on-one meetings and a fireside chat with investors. Recent positive results from the Phase 2b QUALITY study for enobosarm demonstrate its effectiveness in weight management and preserving lean mass, further supporting Veru's innovative drug development efforts.
Read more →VERU▲ +7.7%on this news
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
Veru Inc. reported positive results from its Phase 2b QUALITY and Maintenance Extension study for enobosarm, showing significant reductions in body weight regain and fat regain after discontinuing semaglutide. The enobosarm treatment preserved lean mass and demonstrated a favorable safety profile. The company plans to advance enobosarm to Phase 3 clinical trials and has secured a meeting with the FDA to discuss the program.
Read more →VERUVeru to Participate in the Virtual BTIG Obesity Health Forum
Veru Inc. has announced its participation in the virtual BTIG Obesity Health Forum, scheduled for June 18, 2025. The company is focused on innovative medicines for cardiometabolic and inflammatory diseases, presenting two late-stage drug candidates, enobosarm and sabizabulin. Enobosarm is undergoing a Phase 2b study aimed at enhancing weight loss while preserving muscle mass, while sabizabulin is positioned to address inflammation in atherosclerotic cardiovascular disease. Encouraging results from ongoing studies could impact the company's future collaborations with the FDA.
Read more →VERUVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
Veru Inc. announced positive safety results from its Phase 2b QUALITY clinical study, demonstrating that the combination of enobosarm and semaglutide leads to improved fat loss and muscle preservation for older patients. The study found that this combination reduced gastrointestinal side effects compared to semaglutide alone. As a result, Veru plans to advance enobosarm to a Phase 3 clinical program and has requested a meeting with the FDA for regulatory clarity. Further efficacy data is expected in the upcoming quarter.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Progr
Veru Inc. has reported its fiscal 2025 second quarter financial results alongside updates on its clinical programs, particularly regarding the enobosarm Phase 2b QUALITY study. The company anticipates unblinded safety data this quarter and plans to request an End of Phase 2 meeting with the FDA to discuss the Phase 3 clinical program. Additionally, a novel oral formulation of enobosarm is progressing towards Phase 1 clinical trials. Overall, positive safety and efficacy data bolster the company's forward momentum in drug development.
Read more →VERUVeru Participates in a Virtual Investor KOL Connect Segment
Veru Inc. announced a Virtual Investor KOL segment featuring a discussion between CEO Mitchell Steiner and Dr. Louis J. Aronne on obesity treatments and GLP-1 drugs. The discussion emphasized Veru's lead program, the Phase 2b QUALITY study for enobosarm, and the company’s focus on innovative treatments for cardiovascular and inflammatory diseases. Veru's drug development pipeline includes enobosarm, aimed at improving body composition, and sabizabulin for inflammation treatment. The announcement reflects Veru's proactive approach to investor engagement and highlights its innovative contributions to the biopharmaceutical landscape.
Read more →VERUVeru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Veru Inc. has reported strong financial results for the second quarter of fiscal 2025, alongside significant progress in its clinical programs. The company anticipates unblinded safety data and efficacy results from the Phase 2b QUALITY study and its extension trial in the upcoming quarter. With promising findings from these studies, Veru is preparing for an End of Phase 2 meeting with the FDA to discuss advancing to Phase 3 clinical trials for its enobosarm treatment. The ongoing studies aim to enhance weight management outcomes for older patients using GLP-1 receptor agonists.
Read more →VERUVeru to Report Fiscal 2025 Second Quarter Financial Results on May 8
Veru Inc. announced a conference call on May 8, 2025, to discuss its fiscal 2025 second quarter financial results and provide a business update. The company is developing enobosarm and sabizabulin for treating cardiometabolic and inflammatory diseases. Recent positive results from the Phase 2b QUALITY trial for enobosarm show its potential to preserve lean body mass while promoting fat loss. However, safety data from ongoing trials have not been fully disclosed yet, and future insights will be awaited in the upcoming months.
Read more →VERUVeru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
Veru Inc. will present findings from its Phase 2b QUALITY clinical study at the upcoming GLP-1-Based Therapeutics Summit in Boston. The study demonstrated that enobosarm, when combined with semaglutide, significantly preserved lean body mass while promoting a greater loss of fat mass compared to placebo. The results are promising for developing therapies targeting obesity in older patients. However, safety data remains blinded, necessitating further evaluation as the study progresses.
Read more →VERUVeru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Veru Inc. announced that its CEO, Dr. Mitchell Steiner, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The company is advancing its late-stage drug development programs, including enobosarm for obesity and sabizabulin for cardiovascular inflammation. Recent results from a clinical trial of enobosarm showed significant improvements in body composition among older patients. Additionally, ongoing studies aim to explore the efficacy and safety of sabizabulin as an anti-inflammatory agent in atherosclerotic cardiovascular disease.
Read more →VERUVeru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Veru Inc. reported promising financial results and progress in clinical programs for the fiscal 2025 first quarter. The company announced positive topline results from the Phase 2b QUALITY study, demonstrating significant benefits of enobosarm combined with semaglutide in preserving lean mass and promoting fat loss in older patients. The study's Independent Data Monitoring Committee recommended continuing the trial, and topline results from the subsequent extension study are anticipated in Q2 2025. Additionally, Veru introduced a new indication for sabizabulin in treating inflammatory conditions of coronary artery disease.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Progra
Veru Inc. reported its fiscal 2025 first-quarter financial results, highlighting successful topline results from the Phase 2b QUALITY study for enobosarm combined with semaglutide. This study met its primary endpoint of preserving lean mass while also demonstrating improved fat loss in older patients. The company plans to progress towards a Phase 3 study based on these positive results and has also announced a new indication for sabizabulin in treating inflammation linked to atherosclerotic coronary artery disease. Financial results and clinical developments were shared during a conference call following the announcement.
Read more →VERUVeru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
Veru Inc. announced it will host a financial results conference call on February 13, 2025, following their positive topline results from the Phase 2b QUALITY clinical trial for enobosarm. The trial demonstrated significant benefits in preserving lean body mass and achieving fat loss in patients with sarcopenic obesity. The company is planning to meet with the FDA regarding the next steps based on the successful outcomes of their clinical trial. The audio webcast will be available on the company's website, with telephonic options for participants.
Read more →VERU▼ -6%on this newsshared move
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Veru Inc. has announced that its Chairman and CEO, Dr. Mitchell Steiner, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. This follows the company's report of positive topline results from the Phase 2b QUALITY clinical trial, which successfully met its primary endpoint regarding the preservation of lean body mass when combined with semaglutide in elderly patients. The trial's findings suggest enobosarm could be crucial in addressing sarcopenic obesity, a prevalent issue among older adults. Veru aims to discuss further developments with the FDA after these favorable outcomes.
Read more →VERU▼ -47.5%on this news
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY (Semaglutide) for Weight Reduction
Veru Inc. announced positive topline results from the Phase 2b QUALITY clinical trial, which evaluated the efficacy of enobosarm in preserving lean mass while patients received WEGOVY for weight reduction. The study demonstrated that enobosarm significantly decreased the loss of lean mass compared to WEGOVY alone and enhanced fat loss. Overall, these results suggest that enobosarm can improve body composition and reduce physical function decline in older individuals undergoing weight loss treatment. Further data will be shared at scientific conferences following the completion of the study extension phase.
Read more →VERUVeru Announces the Sale of the FC2 Female Condom (Internal Condom) Business
Veru Inc. has announced the sale of its FC2 Female Condom business to Riva Ridge Capital Management for $18 million. This strategic decision allows Veru to concentrate on its development of clinical drug therapies. The company anticipates topline results from its enobosarm Phase 2b clinical trial in January 2025. However, this move will lead to a drastic reduction in workforce, with approximately 90% of its employees being laid off.
Read more →VERU▲ +8%on this news
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
Veru Inc. will present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders, discussing muscle-selective anabolics for enhancing GLP-1 RA weight loss drugs. The focus is on the Phase 2b QUALITY clinical trial of enobosarm, targeting muscle preservation in elderly patients with sarcopenic obesity. Preliminary results are expected in January 2025, with further data from an extension trial anticipated in Q2 2025, addressing the potential of enobosarm in maintaining muscle health during weight loss treatment.
Read more →VERUVeru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. announced positive results from a meta-analysis presented at ObesityWeek regarding its drug enobosarm for older patients with obesity. The analysis indicated significant improvements in body composition, including increased lean mass and decreased fat mass among subjects treated with enobosarm compared to placebo. This supports the ongoing Phase 2b QUALITY clinical study, which aims to evaluate enobosarm's effects alongside GLP-1 receptor agonists in preserving muscle during weight loss.
Read more →VERUVeru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
Veru Inc. has announced its upcoming presentation at ObesityWeek on a meta-analysis of four clinical trials supporting the potential of Enobosarm in optimizing weight loss. The presentation is scheduled for November 5, 2024, in San Antonio, Texas. The Phase 2b clinical trial aims to evaluate Enobosarm's safety and efficacy in preserving muscle while facilitating fat loss in elderly patients. With topline results expected in January 2025, the drug could significantly benefit the growing population of sarcopenic obese individuals.
Read more →VERUVeru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. will present research on enobosarm at the upcoming World Obesity and Weight Management Congress, focusing on its potential to preserve muscle while enhancing fat loss in elderly patients. The Phase 2b clinical trial is currently recruiting participants and aims to evaluate safety and efficacy in patients taking GLP-1 receptor agonists. Results from this trial are anticipated in early 2025, with additional studies planned pending funding. The company also emphasizes the growing issue of sarcopenic obesity among older adults.
Read more →VERUVeru to Present at the 2024 Cantor Global Healthcare Conference
Veru Inc. has announced that its CEO, Dr. Mitchell Steiner, will present at the 2024 Cantor Global Healthcare Conference on September 18th. The focus will be on the Phase 2b clinical development program of enobosarm, aimed at enhancing weight loss while preventing muscle loss, particularly for obese elderly patients taking GLP-1 drugs. Enobosarm, a selective androgen receptor modulator, has shown potential in prior studies to improve muscle mass and function. Despite positive aspects, the company acknowledges risks related to trial success, funding needs, and regulatory hurdles.
Read more →VERU▲ +5.3%on this news
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
Veru Inc. has successfully achieved full enrollment for its Phase 2b QUALITY clinical study of enobosarm, aimed at preserving muscle mass in conjunction with the GLP-1 receptor agonist semaglutide. The study will evaluate the drug's efficacy on lean body mass, with topline data expected in January 2025. Veru's latest financial results for the third quarter of fiscal 2024 show an increase in net revenues but a significant net loss year-to-date. Enobosarm's potential was highlighted at several major conferences, emphasizing its role in muscle preservation during weight loss treatments.
Read more →VERU▲ +5.3%on this news
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosar
Veru Inc. has successfully achieved full enrollment of over 150 patients for its Phase 2b QUALITY clinical study of enobosarm, a treatment aimed at preserving muscle mass in patients undergoing treatment with GLP-1 receptor agonists for obesity. The company anticipates topline data on the primary endpoint of lean body mass by January 2025. Enobosarm's development is supported by data presented at major scientific conferences, emphasizing its potential benefits. The study could address the unmet medical need for effective weight management while preserving muscle in older patients, particularly those with sarcopenic obesity.
Read more →VERU▼ -5%on this news
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
Veru Inc. is set to report its fiscal 2024 third quarter financial results on August 8, 2024, alongside a business update. The company is conducting a Phase 2b clinical trial for its drug, enobosarm, targeting sarcopenic obesity in older patients. This trial is actively enrolling participants, with topline results expected by the end of the calendar year 2024. However, the company's progress is contingent upon funding for future studies and the success of ongoing clinical trials.
Read more →VERUVeru to Participate in the BTIG Virtual Biotechnology Conference
Veru Inc. (NASDAQ: VERU) will participate in the BTIG Virtual Biotechnology Conference on August 5th, 2024, aiming to engage with investors. The company is focused on its Phase 2b clinical trial of enobosarm, targeting muscle preservation and fat loss in elderly patients with sarcopenic obesity receiving GLP-1 RA treatments. Topline results from this trial are expected by the end of 2024. The company also has plans for further studies involving enobosarm in other indications, demonstrating its commitment to addressing significant health challenges.
Read more →VERU▲ +8.5%on this news
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
Veru Inc. announced its participation in the Leerink Therapeutics Forum focused on Immunology and Metabolism on July 9, 2024, in Boston. The company's Phase 2b clinical trial of enobosarm aims to evaluate safety and efficacy in preserving muscle and augmenting fat loss among elderly patients with sarcopenic obesity. The trial is actively enrolling patients across 15 sites in the U.S. Topline results are expected by the end of 2024, highlighting the potential therapeutic application of enobosarm alongside GLP-1 RA treatments.
Read more →VERU▲ +9%on this news
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
Veru Inc. announced positive results from two late-breaker presentations at the American Diabetes Association's 84th Scientific Sessions. These presentations highlighted the safety and efficacy of enobosarm, indicating a well-tolerated medication with no significant increase in gastrointestinal side effects. Data suggest enobosarm effectively preserves muscle mass while reducing fat in older patients suffering from sarcopenic obesity. The Phase 2b clinical trial is actively enrolling participants, aiming for topline results by the end of 2024.
Read more →VERUVeru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Veru Inc. has adjourned its Annual Meeting of Shareholders due to insufficient quorum, with only 49.6% of shares voted. The rescheduled meeting will occur on June 27, 2024. This adjournment raises concerns over shareholder engagement, which is crucial for the company's decision-making processes. Despite this setback, Veru is actively developing innovative treatments for various metabolic and oncological conditions.
Read more →VERUVeru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
Veru Inc. is reminding shareholders to vote ahead of the deadline for its 2024 Annual Meeting set for June 18, 2024. The company focuses on the development of innovative biopharmaceuticals for obesity and ARDS. Their drug candidates, enobosarm and sabizabulin, are in late-stage development, with enobosarm targeting muscle preservation and cancer treatment. Veru also highlights the commercial availability of the FDA-approved FC2 Female Condom, adding to their product portfolio.
Read more →VERUVeru to Present at the American Diabetes Association's 84th Scientific Sessions
Veru Inc. will present two key studies at the American Diabetes Association's 84th Scientific Sessions in June 2024, focusing on the safety and efficacy of enobosarm in patients with sarcopenic obesity. These presentations will highlight the potential of enobosarm to optimize weight loss while preserving muscle mass. The company is also conducting a Phase 2b clinical trial and anticipates topline results by the end of 2024. Veru continues to develop its innovative therapies targeting obesity and cancer-related muscle loss.
Read more →VERUVeru to Present at the Jefferies Global Healthcare Conference
Veru Inc. announced that its CEO, Dr. Mitchell Steiner, will present at the Jefferies Global Healthcare Conference on June 5, 2024, focusing on the Phase 2b clinical trial of enobosarm. This trial aims to assess enobosarm's efficacy in preserving muscle and augmenting fat loss in older patients receiving GLP-1 drugs for weight loss. The trial is currently enrolling participants across 15 clinical sites in the U.S., with topline results expected by the end of 2024. Additionally, an extension trial is planned to evaluate ongoing effects after discontinuation of GLP-1 therapy.
Read more →VERUVeru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
Veru Inc. has appointed Dr. Steven B. Heymsfield as Principal Investigator for its Phase 2b clinical trial of enobosarm, aimed at preserving muscle mass in patients on GLP-1 RA therapy for weight loss. Dr. Heymsfield, an expert in obesity and metabolism, will oversee clinical sites and contribute to data analysis. The double-blind trial will involve approximately 90 participants, with topline results expected by the end of 2024. This initiative aims to address muscle loss experienced by older adults undergoing weight loss treatments.
Read more →VERU▲ +10.5%on this newsshared move
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
Veru Inc. announced that its Chairman and CEO, Mitchell Steiner, will be a keynote speaker at Biomed Israel 2024. The keynote will address the impact of GLP-1 receptor agonists on muscle loss and weight rebound. Steiner will emphasize strategies to enhance weight loss efficacy while preserving muscle mass, targeting sarcopenic obesity patients. The conference is scheduled for May 21-23, 2024, in Tel Aviv, Israel.
Read more →VERU▼ -12.3%on this news
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of it
Veru Inc. has announced its fiscal 2024 second quarter financial results, highlighting the launch of a Phase 2b clinical study for enobosarm, which aims to address muscle preservation in patients undergoing weight loss treatment with GLP-1 drugs. The trial is currently enrolling participants, and results are expected by the end of 2024. Additionally, a Scientific Advisory Board comprising notable medical experts has been established to guide the development of enobosarm. The company is actively engaging with the medical community, presenting at multiple upcoming conferences.
Read more →VERU▼ -12.3%on this news
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
Veru Inc. has reported its fiscal 2024 second quarter financial results and announced advancements in its enobosarm clinical program focused on weight loss. The Phase 2b clinical trial for enobosarm, in combination with semaglutide, is currently recruiting participants, targeting patients with sarcopenic obesity or older overweight individuals. Financially, the company has experienced a drop in revenues but a notable decrease in operating losses indicates improved financial management. The company's anticipated topline results for the enobosarm study are expected by the end of 2024, signaling a promising development phase.
Read more →VERU▲ +10.1%on this news
Veru to Present at the GLP-1 Based Therapeutics Summit
Veru Inc. will present at the GLP-1 Based Therapeutics Summit on May 15-16, 2024, focusing on their innovative drug enobosarm. The presentation is aimed at discussing how enobosarm may help prevent muscle loss and enhance weight loss when combined with GLP-1 receptor agonist therapies. Veru's ongoing Phase 2b clinical trial will evaluate the safety and efficacy of enobosarm in patients with sarcopenic obesity. Initial results from this trial are anticipated by the end of 2024, with further extension studies planned for 2025.
Read more →VERU▲ +10.4%on this news· ran to +21% by day 1shared move
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
Veru Inc. has announced a conference call scheduled for May 8, 2024, to discuss its second quarter financial results and provide a business update. The company is focused on developing innovative medicines for muscle preservation, metabolic diseases, and oncology. Their drug development includes late-stage clinical trials for enobosarm and sabizabulin. However, the advancement of sabizabulin relies on securing external funding, highlighting some financial uncertainties.
Read more →VERU▲ +8%on this news· ran to +30% by day 3shared move
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru Inc. has enrolled the first patients in its Phase 2b clinical trial for enobosarm in combination with semaglutide, focused on high-quality weight loss. The trial, involving about 90 participants, aims to evaluate the efficacy of enobosarm in preserving muscle and augmenting fat loss in elderly patients. Topline clinical results are anticipated by the end of 2024, with further extension studies planned. This trial addresses significant concerns regarding muscle loss in patients undergoing weight loss therapy using GLP-1 receptor agonists.
Read more →VERU▼ -8.3%on this newsshared move
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Veru Inc. announced its participation in the AACE 2024 Annual Meeting, scheduled for May 9-11, 2024, where it will present late-breaking research on enobosarm. This drug targets muscle preservation and fat loss in older adults dealing with obesity, reflecting Veru's focus on metabolic diseases. The Phase 2b clinical trial's topline results are anticipated by the end of the year, with further developments following an extension trial in 2025. Veru is also exploring other indications and has an FDA-approved product on the market.
Read more →VERU▲ +8.6%on this news
Veru Announces Date of 2024 Annual Meeting of Shareholders
Veru Inc. has announced that the 2024 Annual Meeting of Shareholders is scheduled for June 18, 2024, following the filing of an amendment to its Annual Report on Form 10-K/A and its Quarterly Report on Form 10-Q. This meeting will provide shareholders with updates on the company's ongoing projects, including the drug development programs for enobosarm and sabizabulin. The company is positioning itself as a late clinical-stage biopharmaceutical firm focused on metabolic diseases and oncology. With the filing completed, Veru will issue new notices and proxy cards to shareholders entitled to vote.
Read more →VERUVeru Reschedules Annual Meeting of Shareholders
Veru Inc. has announced the rescheduling of its 2024 Annual Meeting of Shareholders, originally set for March 26, 2024, due to the need to restate its historical financial statements. The restatement arises from a discrepancy in reported research and development expenses, with the company indicating that its cash on hand is expected to last longer than previously stated. The filing of these restated financial statements is anticipated by April 15, 2024, allowing shareholders to review them prior to the meeting.
Read more →VERUVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Veru Inc. announces the appointment of Dr. Louis Aronne as Chief Medical Advisor to advance its enobosarm program aimed at high-quality weight loss. Enobosarm, an oral selective androgen receptor modulator, is intended to minimize muscle loss while augmenting fat loss, particularly when combined with GLP-1 receptor agonist drugs. Dr. Aronne's extensive expertise in obesity treatment will support the upcoming Phase 2b clinical trial aimed at elderly patients with sarcopenic obesity. The trial is set to begin in April 2024, with results expected by the end of the year.
Read more →VERUVeru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Veru Inc. received a notice from Nasdaq regarding its failure to timely file a Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023. This notification indicates non-compliance with Nasdaq Listing Rule 5250(c)(1), giving Veru 60 days to submit a plan for regaining compliance. Despite the setback, the company reported that their actual cash reserves are expected to last longer than initially anticipated, as their R&D expenses were overestimated. Veru continues to work on filing the necessary documentation to comply with regulatory requirements.
Read more →VERUVeru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Veru Inc. has announced the establishment of a new Scientific Advisory Board to advance its enobosarm program, a selective androgen receptor modulator aimed at facilitating quality weight loss. The board includes several experts in obesity, metabolic diseases, and clinical research, which strengthens the program's credibility. The goal is to utilize enobosarm in combination with GLP-1 RA drugs to improve fat loss while preserving muscle mass in overweight patients. This initiative reflects Veru's commitment to addressing challenges in weight management and obesity-related health issues.
Read more →VERU▼ -6.6%on this news
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2024 First Quarter Financial Highlights Company receives
Veru Inc. reported its fiscal 2024 first-quarter financial highlights, including the receipt of FDA clearance for an Investigational New Drug application for enobosarm in combination with GLP-1 drugs. The company plans to initiate a Phase 2b clinical study aimed at providing higher quality weight loss while preserving muscle mass, expected to commence in April 2024. Veru also completed a public offering, bringing its cash reserves to $40.6 million, which will support its ongoing research and development efforts.
Read more →VERU▼ -6.6%on this news
Veru Reports Fiscal 2024 First Quarter Financial Highlights
Veru Inc. announced its fiscal 2024 first quarter highlights, including FDA clearance for the IND of enobosarm, aimed at improving weight loss treatments. The company plans to initiate a Phase 2b obesity study by April 2024 while securing $35.2 million through a recent public offering to support its development efforts. The current trials focus on enobosarm's potential to prevent muscle loss during weight loss therapy, addressing a significant medical need. However, funding challenges remain for other projects, such as the development of sabizabulin for COVID-19 related ARDS.
Read more →VERU▼ -10.1%on this news· ran to -22% by day 3shared move
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Veru Inc. has received FDA clearance for its IND application to initiate a Phase 2b clinical trial for enobosarm, a selective androgen receptor modulator. This trial aims to evaluate the efficacy of enobosarm in preserving muscle mass while enhancing fat loss in sarcopenic obese or overweight elderly patients using GLP-1 receptor agonists for weight loss. The trial is set to begin by April 2024, with topline results expected by the end of 2024.
Read more →VERUVeru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Veru Inc. announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, where CEO Mitchell Steiner will provide updates on the Phase 2b clinical program for enobosarm, aimed at aiding weight loss while preventing muscle loss in patients. The company also emphasized its broader pipeline focused on obesity, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Notably, the development of sabizabulin for ARDS remains pending funding. The webcast of the presentation will be accessible on the company's website post-event.
Read more →VERUVeru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
Veru Inc. announced that it will host a conference call on February 8, 2024, to discuss its fiscal 2024 first quarter financial results and provide a business update. The company is focused on developing treatments for obesity, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its drug development includes late-stage molecules such as enobosarm and sabizabulin, although progress is contingent upon securing external funding for ongoing trials. The company also offers an FDA-approved product, the FC2 Female Condom, as part of its portfolio.
Read more →VERUVeru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
Veru Inc. has submitted an Investigational New Drug (IND) application to the FDA for enobosarm, aimed at preventing muscle loss and augmenting fat loss in combination with GLP-1 drugs for weight loss. This initiative is particularly focused on addressing the needs of sarcopenic obese patients, who risk critical muscle loss when using GLP-1 medications. A Phase 2b clinical trial is planned to evaluate the safety and efficacy of enobosarm, with the primary endpoint centered on changes in lean body mass. The results of the trial are expected in late 2024, which could significantly impact treatment options for obesity.
Read more →VERU▲ +5.7%on this news
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
Veru Inc. announced an upcoming investor call scheduled for January 4, 2024, to discuss recent financing and its strategic focus on the development of enobosarm as a treatment for weight loss in certain patient populations. The company plans to conduct a Phase 2b trial that will evaluate the drug's effectiveness in sarcopenic obese elderly patients using GLP-1 receptor agonists. CEO Mitchell S. Steiner highlighted the promising results from previous studies of enobosarm and expressed confidence that their financing will support their clinical goals. The investor call will also provide updates on the company's overall drug pipeline.
Read more →VERU▼ -8.9%on this newsshared move
Veru Announces Pricing of Public Offering of Common Stock
Veru Inc. has announced the pricing of its underwritten public offering of 45,833,333 shares of common stock at $0.72 per share, aiming to raise approximately $33 million. The proceeds will predominantly fund a Phase 2b clinical trial for enobosarm, targeting muscle loss in elderly patients. Additionally, some funds will be allocated for working capital and general corporate purposes. The offering is expected to close on or about December 18, 2023, pending customary closing conditions.
Read more →VERUVeru Announces Proposed Public Offering of Common Stock MIAMI, FL
Veru Inc. has announced a proposed public offering of its common stock to finance its clinical development programs. The company aims to primarily use the proceeds for a Phase 2b trial evaluating enobosarm for elderly patients at risk of muscle atrophy. The offering is contingent on market conditions, and Veru has granted underwriters a 30-day option to purchase additional shares. This financial move highlights the company's ongoing efforts to advance its drug development initiatives.
Read more →VERUCurrently approved GLP-1 receptor agonist drugs for the treatment of obesity have demonstrated significant loss of both fat and muscle in obese patients Weight loss drugs GLP-1 receptor agonists demonstrated a 6.2-12.4%
Current GLP-1 receptor agonist drugs have shown to significantly support weight loss in obese patients, achieving an average total weight loss of 6.2-12.4% according to clinical trials. VERU is exploring the use of enobosarm in combination with GLP-1 agonists to target obesity and mitigate muscle wasting, but it faces risks regarding the replication of past clinical results and the uncertainty surrounding FDA approval processes. The company's funding and execution of clinical studies also present challenges that could impact the overall development of their therapies.
Read more →VERUVeru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic , Wegovy , or Mounjaro , to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
Veru Inc. has reported promising data on its agent enobosarm from five clinical studies involving older adults. The research demonstrates that enobosarm effectively decreases fat mass while increasing muscle mass and improving physical function. Plans are underway for a Phase 2b clinical trial to evaluate the combination of enobosarm with GLP-1 weight-loss drugs like Ozempic and Wegovy, aimed at optimizing fat loss while preventing muscle wasting. Enrollment for the study is expected to begin in the first quarter of 2024.
Read more →VERUVeru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
Veru Inc. has reached an agreement with the FDA to design a new Phase 3 clinical trial for sabizabulin, aiming to treat hospitalized adult patients with any type of viral acute respiratory distress syndrome (ARDS). This broader indication includes the treatment of patients affected by tripledemic viruses such as Influenza, RSV, and SARS-CoV-2. The trial, which could begin enrollment in Q4 2023, will study 408 patients and assess the drug's efficacy in reducing all-cause mortality. If successful, the study could provide sufficient data for NDA submission, supported by the drug's Fast Track designation.
Read more →VERU▲ +11%on this news
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Veru Inc. will be represented by CEO Mitchell Steiner at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th. The event highlights the company's focus on developing treatments for metastatic breast cancer and viral ARDS. Veru’s late-stage clinical trials include promising work on sabizabulin for COVID-19 and enobosarm for breast cancer. The company's innovative approaches and regulatory communications indicate a proactive stance in both oncology and infectious disease sectors.
Read more →VERUVeru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Veru Inc. announced clinical data from the discontinued Phase 3 ARTEST trial of enobosarm, a novel androgen receptor targeting agent for AR+ ER+ HER2- metastatic breast cancer. The trial showed a response rate of 20% for enobosarm in patients with fewer than three prior endocrine therapies, while standard care yielded no responses. Overall, enobosarm was well tolerated, prompting the company to prioritize further clinical development in the ongoing Phase 3 ENABLAR-2 study. This study aims to assess enobosarm’s efficacy as a second-line treatment, potentially engaging a larger patient population.
Read more →VERUVeru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Veru Inc. announced that its CEO, Mitchell Steiner, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. The company is focused on developing novel therapies for metastatic breast cancer and viral ARDS, with ongoing clinical trials for its lead candidates, including enobosarm and sabizabulin. Notably, sabizabulin has shown significant efficacy in reducing mortality in COVID-19 patients, and the company continues to advance its research despite facing common industry challenges. Future plans include meetings with the FDA to discuss further studies and product development.
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2023 Third Quarter Financial Results Company receives fu
Veru Inc. reported its fiscal 2023 third quarter financial results, highlighting progress in its clinical programs, including the ENABLAR-2 trial for enobosarm in metastatic breast cancer. The company has received further regulatory clarity from the FDA, and plans to expand its sabizabulin study to encompass various viral lung infections. Additionally, Veru achieved a notable reduction in cash burn during the quarter, supporting its financial stability. Positive preclinical data for sabizabulin against both influenza and poxvirus were also reported.
Read more →VERUVeru Reports Fiscal 2023 Third Quarter Financial Results
Veru Inc. reported its fiscal 2023 third quarter results, highlighting progress in its clinical programs and financial management. The company has received FDA regulatory clarity for its Phase 3 ENABLAR-2 study of enobosarm in metastatic breast cancer and plans to expand its sabizabulin study to address various viral infections. Additionally, Veru announced positive preclinical results for sabizabulin and a significant reduction in cash burn, bolstering its financial position. The firm also successfully executed the sale of its ENTADFI product, which could yield further financial benefits.
Read more →VERUVeru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
Veru Inc. is set to report its fiscal 2023 third quarter financial results on August 10, 2023. The company will host a conference call to discuss these results and provide a business update. Fundamental developments include ongoing clinical trials for its cancer therapies and a promising COVID-19 treatment, sabizabulin, which has demonstrated significant efficacy in trials. Veru's product portfolio also encompasses a sexual health division and is focused on addressing vital public health threats, such as smallpox and Ebola virus treatments.
Read more →VERUVeru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Veru Inc. has announced that its research partner, the University of Tennessee Health Science Center (UTHSC), has received two federal grants totaling over $4 million from the U.S. Department of Defense and the National Cancer Institute. These funds will support UTHSC's research into new oncology drugs targeting several high unmet need cancer indications. With their partnership, Veru has the potential to further develop these novel agents derived from the research. The collaboration indicates a promising pathway for advancing cancer treatments, particularly for metastatic and drug-resistant cancers.
Read more →VERUVeru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
Veru Inc. has announced the appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board. Both physicians bring extensive experience in critical care and infectious diseases, enhancing Veru's strategic focus on advancing their drug candidate sabizabulin, aimed at treating viral-induced ARDS. This addition to the advisory board is expected to guide the company's efforts in developing potentially lifesaving treatments amidst the ongoing threat of viral diseases.
Read more →VERUVeru to Present at the Jefferies Healthcare Conference
Veru Inc. announced that its Chairman and CEO, Dr. Mitchell Steiner, will present at the Jefferies Healthcare Conference on June 7, 2023. The company is in late-stage clinical development for treatments targeting breast cancer and COVID-19, with notable advancements in its clinical trials. Veru has achieved significant milestones, including Fast Track designation for its COVID-19 treatment, sabizabulin, which has demonstrated promising results in reducing patient mortality. The company also plans further studies addressing additional viral threats.
Read more →VERU▼ -17.4%on this news· ran to -28% by day 3
Investor Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Media Contact: Hannah Gendel Manager, Corporate Communications Email: media@verupharma
Veru Inc. reported its fiscal 2023 second-quarter financial results and announced an agreement with the FDA to advance a confirmatory Phase 3 clinical trial for sabizabulin, aimed at hospitalized COVID-19 patients. The company also revealed positive preclinical data for sabizabulin related to influenza and poxviruses. Additionally, financial agreements totaling up to $100 million will enhance the company's capital resources. Looking ahead, Veru plans a Phase 2b/3 study for enobosarm in metastatic breast cancer, with clinical results anticipated in 2024.
Read more →VERU▼ -17.4%on this news· ran to -28% by day 3
Veru Reports Fiscal 2023 Second Quarter Financial Results
Veru Inc. reported its fiscal 2023 second quarter financial results, highlighting a significant agreement with the FDA for a confirmatory Phase 3 clinical trial of sabizabulin for COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS). The company successfully sold its ENTADFI product, generating $20 million plus additional potential from sales milestones. It also reported promising preclinical data for sabizabulin in the treatment of influenza induced ARDS as well as other developments in breast cancer treatments. Financially, Veru secured a common stock purchase agreement for up to $100 million, enhancing its capital position.
Read more →VERUVeru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Veru Inc. has announced a significant step forward in their COVID-19 treatment efforts by finalizing the design for a confirmatory Phase 3 clinical trial of sabizabulin with the FDA. This trial aims to evaluate the treatment in hospitalized adult patients at high risk for acute respiratory distress syndrome (ARDS) and will expand the patient population eligible for the study. If the trial shows favorable efficacy, Veru may consider submitting a request for Emergency Use Authorization or New Drug Application. Enrollment for the trial is projected to begin in the second half of 2023, with the first interim analysis expected in 2024.
Read more →VERUVeru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
Veru Inc. has announced a common stock purchase agreement with Lincoln Park Capital Fund, allowing for the purchase of up to $100 million of its stock over the next 36 months. This agreement gives Veru control over the timing and amount of stock sales, potentially bolstering its financial resources for ongoing clinical programs, including cancer and COVID-19 treatments. The company aims to utilize proceeds from the agreement to advance its most critical drug candidates and general corporate purposes.
Read more →VERUVeru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
Veru Inc. is scheduled to release its fiscal 2023 second quarter financial results on May 11, 2023, along with a business update via a conference call. The company is actively involved in developing treatments for breast cancer and COVID-19, with promising results from its Phase 3 trials for sabizabulin, which has been granted Fast Track designation by the FDA. Additionally, Veru's partnership with Eli Lilly for its oncology program highlights its collaborative approach to drug development.
Read more →VERU▲ +16.5%on this news· ran to +37% by day 1
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
Veru Inc. has announced the sale of its ENTADFI business to Blue Water Vaccines for an upfront payment of $20 million, plus potential milestone payments totalling up to $80 million. This transaction is expected to provide the company with financial flexibility to support its ongoing drug development programs, particularly for enobosarm in breast cancer and sabizabulin for SARS-CoV-2. Veru's pipeline developments are crucial as they aim to produce Phase 3 clinical trial data in 2024.
Read more →VERUVeru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom in U.S. Public Health Sector
Veru Inc. has entered into a Purchasing Agreement with Afaxys Group Services to supply its FC2 Female Condom through Afaxys's Group Purchasing Organization. This partnership aims to enhance access to affordable sexual and reproductive healthcare for up to 31 million individuals reliant on community public health centers. The FC2 Female Condom is FDA-approved and offers protection against unintended pregnancies and sexually transmitted infections, including HIV/AIDS. This agreement reflects a commitment to improving family planning options in the U.S. public health sector.
Read more →VERUVeru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Veru Inc. has announced promising results from a preclinical study demonstrating that sabizabulin effectively inhibits the release and spread of poxvirus in infected cells. The company is expanding its study to include treatments for smallpox and plans to meet with the FDA regarding regulatory steps under the Animal Rule. Sabizabulin's antiviral properties and its potential utility in addressing severe respiratory conditions related to viral infections are significant components of this research. The findings highlight sabizabulin's role as a host-targeted antiviral agent with broad implications for global public health.
Read more →VERUVeru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Veru Inc. has announced promising preclinical results for sabizabulin in reducing inflammation and improving outcomes in influenza-induced Acute Respiratory Distress Syndrome (ARDS) models. The data suggests its potential use as a broad antiviral and anti-inflammatory agent, building on positive Phase 3 COVID-19 clinical trial results. The company plans to conduct a Phase 3 clinical study specifically for hospitalized influenza patients at high risk for ARDS. Additionally, an expedited meeting with the U.S. FDA has been granted for further development of the COVID-19 program.
Read more →VERUVeru to Present at the Oppenheimer 33rd Annual Healthcare Conference
Veru Inc. has announced that its CEO, Dr. Mitchell Steiner, will present at the Oppenheimer 33rd Annual Healthcare Conference. During the presentation, the company will outline its corporate strategy focusing on clinical development in infectious diseases and oncology, with Phase 3 clinical trial data expected in 2024. However, the company also highlighted various risks, including the uncertainty of successful commercialization and reliance on external financing.
Read more →VERUVeru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
Veru Inc. announced that the FDA has declined its request for Emergency Use Authorization for sabizabulin, aimed at treating hospitalized COVID-19 patients at high risk for ARDS. Despite this setback, the FDA expressed willingness to assist Veru in developing the treatment and provided feedback on a potential Phase 3 study protocol that could support future authorization. The company's management emphasized their determination to continue pursuing regulatory approval for the potentially life-saving drug, amidst the ongoing impact of COVID-19 in the U.S.
Read more →VERU▼ -22.6%on this news
Veru Reports Fiscal 2023 First Quarter Financial Results
Veru Inc. reported its financial results for the fiscal 2023 first quarter and provided updates on its drug development programs. The company is seeking emergency authorization for its COVID-19 treatment, sabizabulin, which has shown significant efficacy in clinical trials. Additionally, Veru is progressing with its oncology pipeline, including Phase 3 studies for treatments targeted at breast and prostate cancer. However, the company also noted a decrease in revenues and an increase in development costs during this quarter.
Read more →VERUVERU 3-DAY DEADLINE ALERT: Hagens Berman Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys Before Feb. 6th Deadline in Securities Class Action
Hagens Berman is urging investors of Veru Inc. (VERU) who experienced significant losses to contact their attorneys before the Feb. 6, 2023 deadline for a securities class action. The lawsuit alleges that Veru misrepresented data from their Phase 3 trial and had insufficient communication with the FDA regarding sabizabulin, their COVID-19 treatment. This led to a marked drop in share price after the FDA advisory committee voted against approval, revealing uncertainties in clinical data.
Read more →VERUVERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU)
Bernstein Liebhard LLP has announced a class action lawsuit against Veru Inc. for allegedly misleading investors regarding the efficacy data of their COVID-19 treatment, sabizabulin. The lawsuit covers shareholders who acquired Veru stock between May and November 2022. It claims that Veru provided false information that led investors to believe the data from a Phase 3 trial was sufficient for Emergency Use Authorization. Following an unfavorable vote from the FDA advisory committee, Veru's stock price significantly declined.
Read more →VERUVeru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
Veru Inc. announced a conference call to discuss its fiscal 2023 first quarter financial results, scheduled for February 9, 2023. The company is focused on developing innovative treatments for COVID-19 and other conditions, highlighted by its promising drug sabizabulin, which shows significant efficacy in reducing deaths among hospitalized COVID-19 patients. Additionally, Veru intends to provide updates on ongoing regulatory reviews across various global markets. While optimistic about its potential, the company acknowledges the inherent risks in drug development and market success.
Read more →VERUVERU 2-WEEK DEADLINE ALERT: Hagens Berman Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys Before Feb. 6th Deadline in Securities Fraud Class Action
Veru Inc. is facing a securities fraud class action as investors with significant losses are urged to act before the February 6 deadline. The allegations suggest that Veru misrepresented the data from its Phase 3 trial for its COVID-19 treatment, sabizabulin. On November 9, 2022, the FDA advisory committee voted against approving the drug under the Emergency Use Authorization pathway, contributing to a 53% drop in Veru's stock price. The law firm Hagens Berman is leading the investigation into these claims.
Read more →VERU▲ +7.8%on this news· ran to +18% by day 3
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
Veru Inc. has appointed Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board. Dr. Ho, a leading figure in viral research, is expected to bolster Veru's development efforts, particularly concerning sabizabulin for COVID-19 and other viral diseases. His record of significant contributions to HIV therapy and current work on SARS-CoV-2 make him a valuable addition. Veru recently concluded a Phase 3 trial demonstrating the efficacy of sabizabulin, further emphasizing its potential in treating high-risk COVID-19 patients.
Read more →VERU▲ +7.8%on this news· ran to +18% by day 3
Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations
Block & Leviton LLP has filed a class action lawsuit against Veru Inc. and certain executives for alleged securities law violations. The lawsuit, filed in the Southern District of Florida, claims that Veru misled investors regarding the efficacy data for its COVID-19 drug, VERU-111, during the period when its stock price saw a significant decline. The complaint specifically addresses misleading statements made by the company about the support for Emergency Use Authorization. Affected investors who bought shares between May 11, 2022, and November 9, 2022, are encouraged to seek legal counsel.
Read more →VERU▲ +5.6%on this newsshared move
VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) in the United States Southern Dist
Read more →VERUVERU INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against Veru Inc.
NEW YORK, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed in the United States District Court for the Southern District of Florida on behalf of shareholders of Veru Inc. (NASDAQ:VERU) (“Ve
Read more →VERUVERU ALERT: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Pending
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 – Nov. 9, 2022 Lead Plaintiff Deadline: Feb. 6, 2023 Visit: www.hbsslaw.com/investor-fraud/VERU
Read more →VERUVeru Inc. (VERU) Equity Alert: Contact Robbins LLP for Information About the Class Action Against Veru Inc.
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, for viola
Read more →VERUVERU INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 – Nov. 9, 2022 Lead Plaintiff Deadline: Feb. 6, 2023 Visit: www.hbsslaw.com/investor-fraud/VERU
Read more →VERUVeru Inc. (VERU) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Veru Inc.
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, for viola
Read more →VERUVERU INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against Veru Inc.
LEAD PLAINTIFF DEADLINE IS FEBRUARY 6, 2023 NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed in the United States District Court for the Southern District of Florida on behalf of
Read more →VERUVERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Veru Inc. (NASDAQ: VERU)
Did you lose money on investments in Veru? If so, please visit Veru Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that
Read more →VERUVERU News: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Veru Inc. (NASDAQ: VERU) ("Veru" or the "Company"), any of its executive officers, or others violated securities laws by misrepresenting o
Read more →VERU▲ +5.8%on this newsshared move
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states Sabizabulin also under review for potential emerge
Read more →VERUVeru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio webcast on Monday, De
Read more →VERU▼ -53.6%on this news
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
MIAMI, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today’s meeting of the U.S. Food and Drug Adminis
Read more →VERUVeru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced data from the late-breaker oral presentation of the Phase 3 tr
Read more →VERUVeru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitaliz
Read more →VERUVeru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of induc
Read more →VERU▼ -9.8%on this news
Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company wil
Read more →VERU▼ -18.1%on this newsshared move
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
MIAMI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the U.S. Food a
Read more →VERU▼ -21.1%on this news
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
MIAMI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the U.S. Food a
Read more →VERUVeru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022
MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company wil
Read more →VERUVeru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that Australia’s Ther
Read more →VERU▼ -6.5%on this newsshared move
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Ja
Read more →VERU▲ +36%on this news· ran to +89% by day 3shared move
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
--Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022-- --The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will Receive Expedited Review-- -
Read more →VERU▲ +36%on this news· ran to +89% by day 3shared move
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizab
Investor and Media Contact: Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Terr
Read more →VERUVeru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVI
Read more →VERUVeru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that it will report f
Read more →VERU▲ +13%on this news· ran to +33% by day 3
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant and Clinically Meaningful 55.2% Reduction in Deaths Compared to Placebo in Moderate-Severe Hospitalized COVID-19 Patients - - Key Second
Read more →VERUVerus Signs Distribution Agreement in Florida
Orlando, FL, June 21, 2022 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS), a food and hemp-based products company, is pleased to announce that it has signed its first distribution agreement in Florida featuring products from its joint ve
Read more →VERU▲ +16.8%on this news
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
-- The EUA Submission Follows Positive Phase 3 COVID-19 Clinical Trial in which Sabizabulin Demonstrated a 55.2% Reduction in Death in Hospitalized COVID-19 Patients -- -- The Company is in Discussions with Other Regulatory Agencies Around the World Regarding Emergency Use Autho
Read more →VERU▼ -6.2%on this newsshared move
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
MIAMI, June 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the final result
Read more →VERUVeru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7
MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will
Read more →VERUVeru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022
MIAMI, May 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will
Read more →VERUVeru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joe
Read more →VERU▲ +15.6%on this newsshared move
Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022
MIAMI, May 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will
Read more →VERU▲ +10.7%on this news· ran to +91% by day 3shared move
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
--FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients-- --IDMC Unanimously Votes to Halt the Ongoing Phase 3 Trial
Read more →VERU▲ +10.7%on this news· ran to +91% by day 3shared move
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin
Investor and Media Contact: Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization FDA S
Read more →VERU▼ -8.8%on this news· ran to -33% by day 3
Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
MIAMI, April 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on Thursday, May 12, 2022, before the market opens. Veru’s management will host a conference
Read more →VERU▲ +25.8%on this newsshared move
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that results from the randomized placebo-controlled Phase 2 study of daily, oral sabizabulin in patients with severe COVID-19 at high risk for acute respiratory distre
Read more →VERU▲ +182.3%on this news· ran to +244% by day 3
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
-- Independent Data Monitoring Committee Unanimously Recommends that Phase 3 Clinical Trial for Sabizabulin for Treatment of Hospitalized COVID-19 Patients at High Risk for ARDS Be Stopped Early Due to Overwhelming Evidence of Efficacy -- -- Sabizabulin Treatment Showed Statisti
Read more →VERUVeru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
MIAMI, March 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that two abstracts were accepted for presentation at the 39th Mi
Read more →VERUVeru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that the Company will present at the Oppenheimer 32nd Annual Hea
Read more →VERUVeru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that updated clinical data from the positive Phase 1b/2 study of s
Read more →VERUVeru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
--Planned Conditional Statistical Power Analysis was Conducted— --Primary Efficacy Study Endpoint Is Proportion of Patients that Die on Study Up to Day 60-- --Global Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients a
Read more →VERU▲ +6.2%on this newsshared move
Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Re
Investor and Media Contact: Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27% --FC2 Prescription Business Entering 6th --FDA App
Read more →VERU▲ +6.2%on this newsshared move
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
--FC2 Prescription Business Entering 6th Year of Growth -- --FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway-- --Company Enters into Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate En
Read more →VERU▲ +6.3%on this news
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio in Phase 3 ENABLAR-2 Trial
-- Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected to Commence During First Quarter of 2022 -- MIAMI, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on develo
Read more →VERU▲ +9.7%on this newsshared move
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
-- Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, South America, and Europe; Clinical Results Expected 1H 2022 -- -- Second Veru Dr
Read more →VERUVeru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th
MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2022 first qu
Read more →VERUVeru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
-- FDA Fast Track Designation is Intended to Expedite the Development and Review of New Drugs to Treat Serious Medical Conditions that Fill Unmet Medical Need -- -- Phase 3 ARTEST Registration Study of Enobosarm in Patients with AR+ ER+ HER2- Metastatic Breast Cancer Who Have Sh
Read more →VERU▲ +5.4%on this news
Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022
MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will present at the H.C. Wainwright BioConnect Co
Read more →VERUVeru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022-- --ENTADFI to Be Marketed and Distributed by Veru’s Direct to Patient Telemedicine and Telepharmacy Services Platform-- --Veru Partne
Read more →VERU▲ +6.3%on this newsshared move
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating
Read more →VERUVeru Reports Record Fiscal 2021 Full-Year Financial Results
--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Dis
Read more →VERUInvestor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Phone: 800-972-0538 Veru Reports Record Fiscal 2021 Full-Year Financial Results FY21 Net Revenues Increase 44%
Investor and Media Contact: Executive Director, Investor Relations and Corporate Communications Veru Reports Record Fiscal 2021 Full-Year FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Phase 3 Sabizabulin COVID-19 C
Read more →VERU▼ -6.1%on this news
Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd
MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2021 fourth q
Read more →VERU▼ -6.1%on this news
Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500
-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets– -- 212% Revenue Growth Over Last Three Fiscal Years from Sexual Health Division-- --Sexual He
Read more →VERUVeru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021
MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will participate in a fireside chat at the Jeffer
Read more →VERUVeru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, validated, and used to select patients who are most likely to respond to enobosarm
Read more →VERU▼ -5.4%on this news
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of
Read more →VERUVeru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the Phase 1b/2 study of sabizabul
Read more →VERUVeru to Present at Three Upcoming Healthcare Investment Conferences
MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the following upcoming healthcar
Read more →VERU▲ +6.9%on this news
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter
--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs— --Nine-Month FY21 Year to Date Net Revenues Increased 48% to $46M, also a Record High, Even Exceeding Any Prior Full Fiscal Year Net Revenues— --Late Clinical St
Read more →VERU▲ +6.9%on this news
Sam Fisch 800-972-0538 Director of Investor Relations Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter Q3 FY21 Net Revenues Increase 71% to $18M and Gross
Director of Investor Relations Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs Nine-Month FY21 Year to D
Read more →VERUVeru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th
MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 third qu
Read more →VERUVerus International Signs 3rd U.S. Distributor – Provides CEO Update
Gaithersburg, MD, July 12, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS), an international food, CBD and hemp-based products company, is pleased to announce that it has signed its 3rd U.S. distributor for its Pachyderm CBD and Waff
Read more →VERUVeru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress
MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical stu
Read more →VERUVeru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
--Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have also become resistant to abiraterone or
Read more →VERUVerus International Reports Fiscal 2021 Q2 Financial Results; Posts Significant Improvement in Gross Profit Margins
Gaithersburg, MD, June 22, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS), an international food, CBD and hemp-based products company, reported financial results for the fiscal 2021 second quarter, which ended April 30, 2021. In con
Read more →VERUVeru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021-- MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharm
Read more →VERUVeru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40% AR expression in cancer tissue -- -- Companion diagnostic test to measure AR may
Read more →VERUVeru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting
-- Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of 80 men -- -- Phase 3 VERACITY study to evaluate sabizabulin treatment in men
Read more →VERUVeru to Present at the Jefferies Virtual Healthcare Conference
MIAMI, May 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Jefferies Virtual Healthcare C
Read more →VERUVeru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen re
Read more →VERUVerus International Provides Corporate Update
Gaithersburg, MD, May 21, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC: VRUS), an international food, CBD and hemp-based products company, today is providing a corporate update to inform investors of business trends. Verus is currently in the
Read more →VERUVeru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients
—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities— —Sabizabulin treatment reduced mortality in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome in Phase 2 study— —Enrollment is expected to be completed by
Read more →VERUSam Fisch 800-972-0538 Director of Investor Relations Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues First Patient to Be Enrolled this Week in Phase 3 Clinica
Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hos
Read more →VERUVeru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
-- First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients-- --New Drug Application Accepted for Review by FDA for Proprietary TADFIN Daily Oral Dosing Combination for BPH; PDUFA Date December 2021--
Read more →VERUVERUS INTERNATIONAL, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that it has filed a federal securities class action lawsuit against Verus International, Inc. in the United States District Court for the District of Maryland
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) reminds investors that it has filed a federal securities class action lawsuit in the United States District Court for the District of Maryland on behalf of all persons or ent
Read more →VERUVeru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
MIAMI, May 05, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the clinical results from the Phase 2 clinical study of enobos
Read more →VERUVerus International Releases CEO Corporate Update Letter
Gaithersburg, MD, April 29, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS), an international food, CBD and hemp-based products company, today released a corporate update letter from its CEO Andy Dhruv. Valued Shareholders, I have
Read more →VERUVeru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th
MIAMI, April 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 second
Read more →VERUVERUS INTERNATIONAL, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a federal securities class action lawsuit against Verus International, Inc. in the United States District Court for the District of Maryland
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) announces that it has filed the initial federal securities class action lawsuit in the United States District Court for the District of Maryland on behalf of all persons or
Read more →VERUVerus International Adds Second Distributor for New Hemp-Based Waffles Line
Gaithersburg, MD, April 22, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) is pleased to report that it has signed a second distributor for its new hemp-based Waffles product line. The new distributor will begin with a 100-store pil
Read more →VERUVeru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
MIAMI, April 21, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that clinical results from the Phase 2 clinical study of enobosar
Read more →VERUVERUS INTERNATIONAL REPORTS FISCAL Q1 2021 FINANCIAL RESULTS; REALIZES 73% IMPROVEMENT IN OPERATING COSTS
Gaithersburg, MD, March 29, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) reported financial results for the fiscal 2021 first quarter ended January 31, 2021. In conjunction with this release, the Company is also providing addition
Read more →VERUVERUS INTERNATIONAL REPORTS 60% INCREASE IN ANNUAL REVENUE
Gaithersburg, MD, March 22, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) reported financial results for the fiscal 2020 fourth quarter and fiscal year ended October 31, 2020. In conjunction with this release, the Company is also p
Read more →VERUVeru to Present at the Oppenheimer 31st Annual Healthcare Conference
MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the Oppenheimer 31st Annual Heal
Read more →VERUVeru Exploring Strategic Alternatives for its Legacy Female Health Business
MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financia
Read more →VERUVeru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference
MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will participate in a fireside chat at the H.C.
Read more →VERUVeru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
– Veru completes expedited end of Phase 2 trial meeting with FDA – – FDA agrees that Phase 2 clinical findings suggest a clinically meaningful benefit for the use of VERU-111 in hospitalized COVID-19 patients at high risk for ARDS – – FDA agrees to advance VERU-111 into Phase 3
Read more →VERUVeru Submits New Drug Application for Proprietary TADFIN for BPH
--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone to treat symptoms of benign prostatic hyperplasia-- --FDA PDUFA Date is expected
Read more →VERUVerus International Names New CEO and Provides Operational Update
Gaithersburg, MD, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) is providing this interim operational update in advance of filing its fiscal year 2020 annual results, which have been slightly delayed due to recent corporat
Read more →VERUVeru Announces Proposed Public Offering of Common Stock
MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today that it intends to offer and sell, subject to market conditions, s
Read more →VERUSam Fisch 800-972-0538 Director of Investor Relations Veru Announces Proposed Public Offering of Common Stock MIAMI
Director of Investor Relations Veru Announces Proposed Public Offering of Common Stock MIAMI February 17, 2021 Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced
Read more →VERUSam Fisch 800-972-0538 Director of Investor Relations Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter Q1 FY21 Net Revenues and Gross Profit of $15M and $
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter Late Clinical Stage Oncology Drug Pipeli
Read more →VERUVeru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter
--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate and Breast Cancers Continues to Advance to Registration Phase 3 Clinical Studies
Read more →VERUVeru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
– Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results – – Primary efficacy endpoint in hospitalized patients shows VERU-111 treatment had statistically significant 81% relative reduction in dea
Read more →VERUVeru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th
MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 first qu
Read more →VERUVeru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR Activating Agent as a Potential Therapy in Patients with ER+ Metastatic Breast Cance
Read more →VERUVerus International Finalizes Distribution and Product Development Agreement with Texas-Based CBD Distributor
Gaithersburg, MD, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUSD) has finalized a distribution and product development agreement (“Agreement”) with Texas-based Toro Imports (“Toro”), one of the largest CBD and related lifes
Read more →VERUVerus International Completes Requirements for Reverse Stock Split
Gaithersburg, MD, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) has completed its previously announced 1-for-500 reverse stock split. The Market Effective Date of the reverse stock split will be published by FINRA and can
Read more →VERUVeru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021
MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the H.C. Wainwright Bioconnect 20
Read more →VERUVerus International Enters Into Agreements with Game On Foods
Gaithersburg, MD, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) is announcing that the Company and its wholly owned subsidiary, Big League Foods, Inc. (“BLF”), entered into a letter agreement (the “Agreement”) with ACG Glo
Read more →VERUVERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- --Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Cl
Read more →VERUVeru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium – --Enobosarm Demonstrated Clinically Meaningful Clinical Benefit Rates, Overall Response Rates, Median Radiographic Progression-Free Survival and
Read more →VERUVeru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results
—FY20 Full-Year Net Revenues and Gross Profit Achieve Historical Highs of $43 Million and $31 Million, Respectively— —Robust Growing Prescription Sales of FC2 Key Growth Driver; Product Sales Expected to Continue Strong Upward Trajectory— —Company’s Late Clinical Stage Oncology
Read more →VERUVeru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer
--Transformation to Premium Oncology Biopharmaceutical Company with Late-Stage Clinical Drug Pipeline Focused on Prostate and Breast Cancer is Complete-- --Company Poised to Initiate Four Oncology Drug Registration Trials in Prostate and Breast Cancer in Calendar Year 2021-- --
Read more →VERUSam Fisch, Director of Investor Relations 800-972-0538 Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results FY20 Full-Year Net Revenues and Gross Profit Achieve Historical Highs
Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results FY20 Full-Year Net Revenues and Gross Profit Achieve Historical Highs of $43 Million and $31 Million, Respectively Robust Growing Prescription Sales of FC2 Key Growth Driver; Product Sales
Read more →VERUVeru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th
MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 fourth
Read more →VERUVERUS INTERNATIONAL REPORTS STRONG PACHYDERM SALES AND GROWING BACKLOG
Gaithersburg, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC Pink: VRUS) is pleased to provide this update on the strong growth trends in its Pachyderm Labs division (“Pachyderm”). The Company is excited to report that it has sold
Read more →VERUVERUS INTERNATIONAL REPORTS RECORD GROWTH AT ELIOT’S NUT BUTTERS DIVISION
Gaithersburg, MD, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to provide this update on new growth initiatives at its Eliot’s Nut Butters Division (“Eliot’s”). Acquired during September 2020, Eliot’s has already
Read more →VERUVERUS INTERNATIONAL ISSUES STRATEGIC UPDATE
Gaithersburg, MD, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is providing this strategic overview in order to update investors on significant corporate events. The Company has begun implementing a strategic plan that it be
Read more →VERUVerus International Issues Update on zc Top Apparel Manufacturing
Gaithersburg, MD, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) reported that it issued a Repayment and Notice of Rescission of Transaction (the “Demand and Rescission Letter”) to ZC Top Apparel Manufacturing, Inc. (“TAM”), a
Read more →VERUVeru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer
MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has fully enrolled its Phase 2 clinical study of VERU-11
Read more →VERUVERUS INTERNATIONAL REPORTS RECORD THIRD QUARTER RESULTS
Gaithersburg, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) reported record results for its third fiscal quarter ended July 31, 2020. In conjunction with this release, the Company is also providing additional details on
Read more →VERUVeru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer
—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program— MIAMI, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that
Read more →VERUVeru to Participate and Present at Four Upcoming Healthcare Investor Conferences
MIAMI, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced its participation in four upcoming healthcare investor conferenc
Read more →VERUVERUS INTERNATIONAL EXPANDS PRODUCT LINE -- ACQUIRES ELIOT’S NUT BUTTERS
Gaithersburg, MD, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that it has acquired Eliot’s Nut Butters (“Eliot’s”), an award-winning small batch, flavored nut butter company based in Portland, Oregon
Read more →VERUVerus International, Inc. CEO Discusses Recent News and International Expansion in a New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, Sept. 01, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Verus International, Inc.'s (“Verus” or the “Company”) (OTCQB: VRUS) CEO, who discusses, among other topics, the development of the Company’s
Read more →VERUVERUS INTERNATIONAL ANNOUNCES NEW HEAD OF VERUS FOODS AMERICA
Gaithersburg, MD, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is excited to provide the following update to highlight increases in senior and other staffing related to its North American operations. The Company is pleased t
Read more →VERUVERUS INTERNATIONAL SECURES RETAIL LICENSE AGREEMENT WITH NATIONAL HOCKEY LEAGUE AND PROVIDES OPERATIONAL UPDATE
Gaithersburg, MD, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that its Big League Foods (“BLF”) division has secured a retail license agreement with the National Hockey League ("NHL") to produce NHL-t
Read more →VERUVERUS INTERNATIONAL TO SUPPLY MEIJER SUPERCENTERS WITH MLB CANDY; ANNOUNCES FIRST SHIPMENTS TO T.J. MAXX AND MARSHALLS
Gaithersburg, MD, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is excited to announce a major new customer, Meijer, Inc. (“Meijer”), one of the largest retailers in the Midwest, with more than 240 supercenters in six states.
Read more →VERUVeru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product
-- Three-Year Multi-Million Unit Extension Agreement – -- Roman Swipes Seeing Rapid Growth through Leading Men’s Digital Health Clinic -- MIAMI, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on develop
Read more →VERUVeru Reports Higher Net Revenues for Fiscal 2020 Third Quarter
--Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021-- --VERU-111 Phase 1b Clinical Trial Results Accepted for Presentation at European Society for Medical Oncology 2020 Congress --
Read more →VERUSam Fisch 800-972-0538 Director of Investor Relations Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VE
Contact: Sam Fisch 800-972-0538 Director of Investor Relations Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Co
Read more →VERUVERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19
--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model-- --VERU-111’s ability to disrupt microtubules has potential for dual drug action against COVID-19: treat SARS-CoV-2 virus infection and reduce Infla
Read more →VERUVERUS INTERNATIONAL SETS INITIAL CBD PRODUCT SHIPMENT SCHEDULE
Gaithersburg, MD, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is providing the following corporate update in order to give analysts and investors a description of current business trends and to offer a roadmap for shipments
Read more →VERUVeru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th
MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 third q
Read more →VERUVeru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation
MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the clinical results from its Phase 1b/2 study of VERU-111 h
Read more →VERUVeru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer
MIAMI, July 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has received regulatory clarity from the U.S. Food and Dr
Read more →VERUVERUS INTERNATIONAL ANNOUNCES NATIONAL IMPLEMENTATION AGREEMENT FOR PACHYDERM LABS PRODUCT LINES
Gaithersburg, MD, July 17, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that it has signed an agreement with a national distributor to introduce Pachyderm Labs (“Pachyderm”) line of consumer cannabidiol (“CBD”)
Read more →VERUVERUS INTERNATIONAL ANNOUNCES NEW EQUITY INVESTMENT AND NOTES PAYABLE UPDATE
Gaithersburg, MD, July 02, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is providing this update to inform analysts and investors of the status of a new equity funding initiative designed to extinguish the Company’s existing debt. Th
Read more →VERUVeru Inc. Added to the Russell 2000 and 3000 Indices
MIAMI, June 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has been added to the Russell 2000® Index and the Russell
Read more →VERUVERUS INTERNATIONAL ANNOUNCES NEW PACHYDERM LABS DIVISION
Gaithersburg, MD, June 25, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce its newest operating division, Pachyderm Labs, which will target the consumer cannabidiol (“CBD”) products market. The division will opera
Read more →VERUVERUS INTERNATIONAL REPORTS RECORD SECOND QUARTER RESULTS
Gaithersburg, MD, June 22, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) reported record results for its second fiscal quarter ended April 30, 2020. In conjunction with this release, the Company is also providing additional details on
Read more →VERUVeru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19
MIAMI, June 19, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, announced that it has enrolled the first patient in its Phase 2 clinical trial of
Read more →VERUVeru to Present at Jefferies Virtual Healthcare Conference on June 2nd
MIAMI, May 26, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the Company will present at the Jefferies Virtual Healthcare
Read more →VERUVERUS INTERNATIONAL ANNOUNCES EXPANSION PLANS FOR U.S. SALES NETWORK
Gaithersburg, MD, May 19, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is providing this update to highlight the positive impact on its operations from the expected restart of professional sports in the United States. The announcemen
Read more →VERUSam Fisch 800-972-0538 Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61% Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety
Contact: Sam Fisch 800-972-0538 Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61% Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable P
Read more →VERUVeru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%
--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 Study Enrolling; Plan to Meet with FDA as Positive Clinical Data Supports Clinical Adv
Read more →VERUVeru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19
--VERU-111’s Ability to Disrupt Microtubules has Potential for Dual Drug Action Against COVID-19: Treat SARS-CoV-2 Virus Infection and Reduce Inflammation Caused by Viral Infection-Induced Cytokine Storm-- --Phase 2 Clinical Study Expected to Commence in Hospitalized COVID-19 Pa
Read more →VERUVeru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th
MIAMI , May 06, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 second
Read more →VERUVeru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program
--VERU-111 Safe and Well Tolerated at Daily Doses 63 mg and Lower; No Significant Neutropenia or Neurotoxicity Observed-- --Evidence of antitumor activity; durable PSA declines, objective tumor regression and stable disease-- --In the eight men who have been treated with at lea
Read more →VERUVERUS INTERNATIONAL ACHIEVES RECORD QUARTERLY REVENUE AND PROVIDES UPDATE TO BUSINESS PROGRESS
Gaithersburg, MD, April 29, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) reported results for its first fiscal quarter ended January 31, 2020. In conjunction with this release, the Company is also providing additional details on rece
Read more →VERUVERUS INTERNATIONAL SCHEDULES FIRST QUARTER FISCAL 2020 FINANCIAL RESULTS CONFERENCE CALL
Gaithersburg, MD, April 27, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) will conduct its first quarter fiscal 2020 financial results and corporate update conference call on Wednesday, April 29, 2020 at 4:30 p.m. Eastern Time (1:30 p
Read more →VERUVERUS INTERNATIONAL ANNOUNCES PROTECTIVE SUPPLY ORDER AND NAMES NEW PRESIDENT OF MEDICAL SUPPLY DIVISION
Gaithersburg, MD, April 24, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS)) is pleased to announce this update on its new medical supply division. The Company has finalized its first order, a $820,000 (USD) agreement for disposable med
Read more →VERUVERUS INTERNATIONAL, INC. REPORTS 116% INCREASE IN QUARTERLY REVENUE AND 135% INCREASE IN ANNUAL REVENUE
Gaithersburg, MD, April 13, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS)) today announced financial results for its fiscal 2019 fourth quarter and fiscal year ended October 31, 2019. In conjunction with this release, the Company is a
Read more →VERUVERUS INTERNATIONAL ACQUIRES CONTROLLING INTEREST IN N95 MASK AND BIOHAZARD SUIT MANUFACTURER
Gaithersburg, MD, April 03, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that it has acquired a controlling 51% interest in ZC Top Apparel Manufacturing, Inc. (“ZC Top”), a Philippines-based maker of reusable N
Read more →VERUVERUS INTERNATIONAL SCHEDULES FISCAL 2019 FINANCIAL RESULTS CONFERENCE CALL
Gaithersburg, MD, April 02, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) will conduct its Fiscal 2019 financial results conference call on Monday, April 13, 2020 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). The Form 10-K (“10-
Read more →VERUVERUS INTERNATIONAL ANNOUNCES ORDERS WITH HOMEGOODS, WEIS MARKETS AND MAJOR LEAGUE STADIUM STORES
Gaithersburg, MD, March 12, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that TJX Companies “TJX” has added HomeGoods stores, which has 716 locations, to its initial order for Major League Baseball (“MLB”) bran
Read more →VERUVERUS INTERNATIONAL ANNOUNCES FIRST ORDERS WITH MAJOR RETAILERS: TJX COMPANIES AND BIG FIVE SPORTING GOODS
Gaithersburg, MD, March 11, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is pleased to announce that it has received initial candy orders from new distributors, sporting goods and national chain customers. These orders mark a major m
Read more →VERUVeru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug
--VERU-111 Targeting Men with Metastatic Castration Resistant Prostate Cancer Who Have Also Become Resistant to Abiraterone or Enzalutamide-- --Phase 2 Study Results Expected by Calendar Year End— MIAMI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate C
Read more →VERUVERUS INTERNATIONAL PROVIDES OPERATIONAL UPDATE
Gaithersburg, MD, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) is providing the following operational update as part of a plan to issue updates during the period leading up to the completion of the delayed fiscal 2019 Form 1
Read more →VERUSam Fisch 800-972-0538 Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57% Completion of VERU-111 Phase 1b Clinical Trial and Initiation of
Contact: Sam Fisch 800-972-0538 Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57% Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY
Read more →VERUVeru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%
--Completion of VERU-111 Phase 1b Clinical Trial and Initiation of Phase 2 Prostate Cancer Clinical Trial in Q2 FY 2020-- --Zuclomiphene Expected to Enter Pivotal Phase 3 Clinical Trial for Treating Hot Flashes in Men with Prostate Cancer on ADT Following Planned Meeting with FD
Read more →VERUVeru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th
MIAMI, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal
Read more →VERUVeru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that two of its abstracts have been accepted for pr
Read more →VERUVeru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
-- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 -- -- Potential to be First FDA-Approved Drug for ADT Induced Hot Flashes -- MIAMI, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology an
Read more →VERUVERUS INTERNATIONAL ENGAGES TOP TEN NATIONAL PUBLIC ACCOUNTING FIRM
Gaithersburg, MD, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) announced today that it has engaged CBIZ Mayer Hoffman McCann, LLC (“CBIZ MHM”) as the Company’s new independent registered public accounting firm. Mayer Hoffman
Read more →VERUSam Fisch 800-972-0538 Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147% Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activ
Contact: Sam Fisch 800-972-0538 Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147% Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Me
Read more →VERUVeru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer-- --VERU-111 Has Promising Signs of Progression Free Survival-- -
Read more →VERUVERUS INTERNATIONAL TO OPEN FIRST MANUFACTURING FACILTIY
Gaithersburg, MD, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) announced today that it is completing a 10,000 square foot manufacturing facility located in Houston, Texas. The facility will operate as a Verus subsidiary unde
Read more →VERUVeru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th
MIAMI, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal
Read more →VERUVERUS INTERNATIONAL, INC. TO PRESENT AT THE 12th ANNUAL LD MICRO MAIN EVENT INVESTOR CONFERENCE ON DECEMBER 10, 2019
Gaithersburg, MD, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) will present at the 12th Annual LD Micro Main Event Investor Conference taking place at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The Company is schedu
Read more →VERUVERUS INTERNATIONAL, INC. TO PRESENT AT NATIONAL INVESTMENT BANKING ASSOCIATION CONFERENCE IN NYC ON NOVEMBER 13, 2019
Gaithersburg, MD, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB: VRUS) will present at the National Investment Banking Association (NIBA) Conference in New York City today at 9:50 a.m. Eastern Time. The NIBA conference is a two-day
Read more →VERUVERUS INTERNATIONAL ACQUIRES A CONTROLLING INTEREST IN NUTRIBRANDS – ENTERS SOUTH AMERICAN MARKET
Gaithersburg, MD, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) today announced that it has acquired a controlling interest in Nutribrands, LLC (“Nutribrands”), a Brazil-based health and nutrition company that owns, imports, a
Read more →VERUVeru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes
-- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes – -- Topline Clinical Data Anticipated Fall 2019 -- MIAMI, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developin
Read more →VERUVERUS INTERNATIONAL, INC. NAMES GENERAL COUNSEL
Gaithersburg, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) today announced that it has named industry veteran Michael McGowan to the role of General Counsel. Michael brings more than 25 years of experience to this new p
Read more →VERUVERUS INTERNATIONAL, INC. REPORTS 154% INCREASE IN QUARTERLY REVENUE; FORECASTS CONTINUED TRIPLE-DIGIT GROWTH
Gaithersburg, MD, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) today announced financial results for its fiscal 2019, third quarter ended July 31, 2019. In conjunction with this release, the Company is also providing additional details o
Read more →VERUVERUS INTERNATIONAL SCHEDULES THIRD QUARTER FISCAL 2019 FINANCIAL RESULTS CONFERENCE CALL
Gaithersburg, MD, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) will hold its third quarter 2019 Financial Results and Corporate Update Conference Call on Tuesday, September 10, 2019 at 4:30 p.m. Eastern Time (1:30 p.m. Pacif
Read more →VERUVERUS INTERNATIONAL ACQUIRES UAE-BASED FRENCH FRY OPERATION
Gaithersburg, MD, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) is pleased to announce that it has entered into an Asset Purchase Agreement to acquire the french fry operations (the “Acquired Assets”) of an established suppli
Read more →VERUVeru to Participate at Three Upcoming Healthcare Investor Conferences in New York
MIAMI, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced its participation at three upcoming healthcare invest
Read more →VERUVeru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
MIAMI, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that it has been invited by NASDAQ to ring the closin
Read more →VERUVERUS INTERNATIONAL SIGNS $13.5 MILLION CREDIT INSURANCE POLICY; SELLS OUT FIRST RUN OF MLB ICE CREAM
Gaithersburg, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) is pleased to announce that it has procured $13.5 million in credit insurance from Euler Hermes, the global leader in trade credit insurance, surety, and related
Read more →VERUVeru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter
Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist 3 Month Depot Formulation for Androgen Deprivation Had Successful PreNDA meeting with FDA for TADFIN for BPH and NDA Submissi
Read more →VERUSam Fisch 800-972-0538 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Tr
Contact: Sam Fisch 800-972-0538 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter Promising Clinical Observations for Both Advancing VERU-111 and Zuclomiphene Prostate Cancer Clinical Trials Added VERU-100, Novel First GnRH Antagonist
Read more →VERUVeru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th
MIAMI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on
Read more →VERUVERUS INTERNATIONAL ANNOUNCES $500,000 LINE OF CREDIT WITH THE COLUMBIA BANK, N.A.
Gaithersburg, MD, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCQB:VRUS) is pleased to announce that it has signed a revolving line of credit (“LOC”) with The Columbia Bank, N.A. (a Fulton Financial Corporation affiliate). The revolvin
Read more →VERUVeru Announces Dismissal of Lawsuit; Prevails on All Counts in Motion for Summary Judgment
MIAMI, July 18, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced the dismissal of litigation against the Company and c
Read more →VERUVERUS INTERNATIONAL SIGNS $605,000 NOTE; INCREASES FUNDED BACKLOG
Gaithersburg, MD, July 08, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC:VRUS) is pleased to announce that it has strengthened its capital structure via a $605,000 fixed-rate convertible note from Eagle Equities, LLC. The note carries a 4% per
Read more →VERUVeru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia
--Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway— -- TADFIN is a First Novel Combination Formulation of Tadalafil and Finasteride for the Treatment of BPH with NDA Submission Anticipated in Summer of 2020-
Read more →VERUVERUS INTERNATIONAL, INC. REPORTS 153% INCREASE IN QUARTERLY REVENUE; FORECASTS RECORD GROWTH FOR FISCAL 2019
Gaithersburg, MD, June 17, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) today announced financial results for its fiscal 2019 second quarter ended April 30, 2019. In conjunction with this release, the Company is also providing additional details o
Read more →VERUVERUS INTERNATIONAL NAMES CHIEF FINANCIAL OFFICER
Gaithersburg, MD, June 07, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC:VRUS) is pleased to announce that Christopher Cutchens has been appointed as the Company’s Chief Financial Officer, effective June 1, 2019. As part of this appointment, M
Read more →VERUVeru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA
— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical
Read more →VERUVERUS INTERNATIONAL ANNOUNCES $500,000 STRATEGIC INVESTMENT FROM ARJ CONSULTING, LLC
Gaithersburg, MD, May 31, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC:VRUS) is pleased to announce that it has received a strategic investment from ARJ Consulting, LLC and lead investor Andrew Garnock. The transaction involved the sale of 41
Read more →VERUVERUS INTERNATIONAL SIGNS NEW 2,500 STORE DISTRIBUTION AGREEMENT
Gaithersburg, MD, May 28, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTC:VRUS) is pleased to announce that it has signed a new distribution agreement to place Major League Baseball (MLB) branded confectionary products into approximately 2,500 l
Read more →VERUVeru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th
MIAMI, May 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that the Company will present at the Jefferies 2019 Gl
Read more →VERUSam Fisch 800-972-0538 Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising Strong Financial Results for Q2 and Y
Contact: Sam Fisch 800-972-0538 Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising Strong Financial Results for Q2 and YTD FY 2019 Company to Host Invest
Read more →VERUVeru Reports Strong Fiscal 2019 Second-Quarter Financial Results
-- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising – -- Strong Financial Results for Q2 and YTD FY 2019 -- -- Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET – MIAMI, May 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc
Read more →VERUVeru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th
MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on
Read more →VERUVerus International Signs $600,000 Note – Provides Operational Update
Gaithersburg, MD, May 01, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCPink:VRUS) is pleased to announce that it has strengthened its capital structure via a $600,0000 fixed-rate convertible note from GS Capital. The note carries a 5% per annu
Read more →VERUVERUS INTERNATIONAL ANNOUNCES ACQUISITION OF BIG LEAGUE FOODS, INC. – GAINS LICENSE WITH MAJOR LEAGUE BASEBALL
Gaithersburg, MD, April 26, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) (OTCPink:VRUS) today announced its acquisition of Big League Foods, Inc. (“Big League Foods”), which has a license with Major League Baseball Properties, Inc. (“MLB”) to sell
Read more →VERUVERUS INTERNATIONAL, INC. REPORTS 145% INCREASE IN QUARTERLY REVENUE, ANNOUNCES LARGEST FUNDED BACKLOG IN COMPANY HISTORY
Gaithersburg, MD, March 25, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) today announced financial results for its fiscal 2019 first quarter ended January 31, 2019. In conjunction with this release, the Company is also providing a more detailed de
Read more →VERUVERUS INTERNATIONAL, INC. REPORTS 101% INCREASE IN ANNUAL REVENUE
Gaithersburg, MD, March 19, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) today announced financial results for its fiscal 2018 fourth quarter and full year ended October 31, 2018. In conjunction with this release, the Company will also provide add
Read more →VERUVeru to Participate in Two Investor Conferences in March
MIAMI, March 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced its participation in two upcoming inve
Read more →VERUVERUS INTERNATIONAL ANNOUNCES $4 MILLION RICE SUPPLY AGREEMENT
Gaithersburg, MD, March 05, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) is pleased to announce that it has received an order from a distributor to deliver approximately $4 million worth of rice annually for the Dubai market. Verus will source thr
Read more →VERUVERUS INTERNATIONAL SIGNS $10 MILLION HONEY SUPPLY AGREEMENT
Gaithersburg, MD, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. (“Verus” or the “Company”) is pleased to announce that it has signed an agreement to supply honey products in Europe and parts of the Middle East. The initial phase of the agreement is expected to gener
Read more →VERUKevin Gilbert 786-322-2213 Veru Reports Strong Fiscal 2019 First Quarter Financial Results Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trial
Contact: Kevin Gilbert 786-322-2213 Veru Reports Strong Fiscal 2019 First Quarter Financial Results Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Company to Host Investor Conference Call on Wed
Read more →VERUVeru Reports Strong Fiscal 2019 First Quarter Financial Results
-- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET -- MIAMI, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Veru In
Read more →VERUVeru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium
MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that four presentations relating to Ver
Read more →VERUVerus International Announces $1.45 Million Financing and Retirement of Notes
Gaithersburg, MD, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Verus International, Inc. (“Verus” or the “Company”) is pleased to announce that it has received $1.45 million in funding, as detailed in a Form 8-K filed today. The notes were placed with two separate instit
Read more →VERUVeru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th
MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology specialty pharmaceuticals, today announced that on Wednesday, February 13, 2019, t
Read more →VERUVeru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer
--Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End-- -- Drug Addresses Significant Unmet Medical Need -- MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated
Read more →VERUVeru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019
MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster presentation at the upcoming 2019 American Society of Clinical Oncology (ASCO) Genitourinary Can
Read more →VERUVeru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and Finasteride Combination tablet met the U.S. Food and Drug Administration’s (FDA
Read more →VERUKevin Gilbert 786-322-2213 Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into B
Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes Stock Offering, Awarded
Read more →VERUVeru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter
-- Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes Stock Offering, Awarded Large FC2 Tender -- Company to Host Investor Conference Call on Thursday, Dece
Read more →VERUVeru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th
MIAMI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on Thursday, December 13, 2018, the company will report financial results for the fourth quarter and fiscal year ended September 30, 2018, be
Read more →VERUVeru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia
-- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that the Compan
Read more →VERUVeru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer
-- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that i
Read more →VERUVeru to Present at Upcoming Healthcare Investor Conferences in New York
MIAMI, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the company’s Chairman, President and Chief Executive Officer, Dr. Mitchell Steiner, will present an overview of the company’s development p
Read more →VERUKevin Gilbert 786-322-2213 Veru Announces Proposed Public Offering of Common Stock MIAMI
Gilbert 786-322-2213 Announces Proposed Public Offering of Common Stock MIAMI September 26, 2018 Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, shares of its common s
Read more →VERUVeru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer
MIAMI, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that it has completed a Pre-Investigational New Drug Application (pre-IND) meeting for VERU-111 in which the Food and Drug Administration (FDA) a
Read more →VERUVeru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month
MIAMI, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that that it has been invited by NASDAQ to ring the closing bell on August 31, 2018, to kick off National Prostate Cancer Awareness Month. Veru Chie
Read more →VERUVeru Announces Additional Information Regarding its South Africa Female Condom Tender Award
MIAMI, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced additional information regarding its recent award of 75% of a 120 million-unit South Africa female condom tender. “The anticipated total revenue of
Read more →VERUVeru Awarded 75 Percent of South Africa Female Condom Tender
-- Overall Tender is for Up to 120 Million Female Condoms Over Three Years -- -- Awarded Up to 29.8 Million FC2 Female Condoms of 40 Million Total for First Year -- MIAMI, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical com
Read more →VERUKevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 Third Quarter Financial Results Investigational New Drug Application with the FDA Accepted for Phase 2 Study of Zuclomiphene VERU-111 Preclinical Efficacy Data
Contact: Kevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 Third Quarter Financial Results Investigational New Drug Application with the FDA Accepted for Phase 2 Study of Zuclomiphene VERU-111 Preclinical Efficacy Data in Four Different Cancers Presented at American
Read more →VERUVeru Reports Fiscal 2018 Third Quarter Financial Results
-- Investigational New Drug Application with the FDA Accepted for Phase 2 Study of Zuclomiphene -- -- VERU-111 Preclinical Efficacy Data in Four Different Cancers Presented at American Society of Clinical Oncology (ASCO) Annual Meeting – -- FC2 Female Condom Business Has Strong
Read more →VERUVeru to Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call on August 14th
MIAMI, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on August 14, 2018, the company will report financial results for its fiscal 2018 third quarter that ended June 30, 2018, before the market o
Read more →VERUVeru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy
-- Intellectual Property Position Strengthened; U.S. Patent Issued for VERU-944, Expiring 2035 -- -- VERU-944 Potentially First FDA-Approved Drug for this Indication -- MIAMI, June 12, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical co
Read more →VERUVeru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th
MIAMI, May 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that the company’s Chairman, President and Chief Executive Officer, Mitchell Steiner, M.D., will present at the Jefferies 2018 Global Healthcare Conf
Read more →VERUVeru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting
MIAMI, May 17, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a novel oral alpha and beta tubulin inhibitor, that showed efficacy in chemotherapy res
Read more →VERUVeru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting
MIAMI , May 17, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity in a highly re
Read more →VERUVeru Reports Fiscal 2018 Second-Quarter Financial Results
-- Promising Oncology Drug Data to be Presented at Upcoming American Urological Association Medical Conference; FDA Waives Drug Application Fee; BE Clinical Studies Results Anticipated for Drugs in 2018; Clinical Trials for VERU-944 and VERU-111 Planned for 2018 -- Company to
Read more →VERUKevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 Second-Quarter Financial Results Promising Oncology Drug Data to be Presented at Upcoming American Urological Association Medical Conference; FDA Waives Drug A
Contact: Kevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 Second-Quarter Financial Results Promising Oncology Drug Data to be Presented at Upcoming American Urological Association Medical Conference; FDA Waives Drug Application Fee; BE Clinical Studies Results Anti
Read more →VERUVeru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th
MIAMI, May 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that on May 9, 2018, the company will report financial results for its fiscal 2018 second quarter that ended March 31, 2018, before the market opens.
Read more →VERUVeru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting
MIAMI, May 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that data from a pre-clinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor showing potent activity against paclitaxel sensitive a
Read more →VERUVeru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Annual EAU Congress
MIAMI, March 16, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on urology and oncology, announced that data from a preclinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity against paclitaxel sens
Read more →VERUVeru to Present at the Oppenheimer 28th Annual Healthcare Conference on March 21, 2018
MIAMI, March 14, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that that the company will present at the Oppenheimer 28th Annual Healthcare Conference at 1:35 p.m. ET on Wednesday, March 21, 2018 at the Westin New York Grand Central, in New York City. A webcas
Read more →VERUVeru Completes $10 Million Synthetic Royalty Financing on FC2 Business
MIAMI, March 05, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that it has completed a $10 million “synthetic” royalty financing on FC2 Female Condom® product sales with SWK Holdings. Veru will use the funds to advance the clinical development of the Company’s
Read more →VERUVeru Reports Fiscal 2018 First-Quarter Financial Results
-- Company Advancing Multiple Drugs from Pipeline; First New Drug Application (NDA) Remains on Track for Submission in 2018; Two Additional NDAs Expected to be Filed in 2019; Promising Oncology Drug Data Presented at Major Medical Conference -- Company to Host Investor Conferenc
Read more →VERUKevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 First-Quarter Financial Results Company Advancing Multiple Drugs from Pipeline; First New Drug Application (NDA) Remains on Track for Submission in 2018; Two A
Kevin Gilbert 786-322-2213 Veru Reports Fiscal 2018 First-Quarter Financial Results Company Advancing Multiple Drugs from Pipeline; First New Drug Application (NDA) Remains on Track for Submission in 2018; Two Additional NDAs Expected to be Filed in 2019; Promising Oncology Dr
Read more →VERUVeru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14
MIAMI, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that on February 14, 2018, the company will report financial results for its fiscal 2018 first quarter ended December 31, 2017, before the market opens. Veru management will host a conference call t
Read more →VERUVeru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Genitourinary Cancers Symposium
MIAMI, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced data from a pre-clinical study of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity against paclitaxel sensitive and resistant prostate cancer models, that will be pres
Read more →VERUVeru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results
-- Fiscal 2017 Marked by Actions to Advance Drug Pipeline; First New Drug Application (NDA) on Track for Submission in First Half of 2018; Three Additional NDAs Expected to be Filed: Two in 2019 and One in 2020 -- Company to Host Investor Conference Call on Friday, January 5, 20
Read more →VERUVeru Acquires Novel Proprietary Formulation for Overactive Bladder
--Addresses Large Population of Men and Women Who Have Overactive Bladders And Difficulty Swallowing Tablets-- --FDA Meeting Confirms Single Bioequivalence Study Path to Approval-- --Expands Offering of Drugs for Long-Term Care and Geriatric Urology-- MIAMI, Dec. 11, 2017 (GLO
Read more →VERUVeru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results
MIAMI, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced the results of the bioequivalence (BE) clinical trial of the company’s proprietary Tamsulosin Delayed Release Sachet (DRS) (Tamsulosin HCl extended-release oral suspension) formulation versus FLOMAX®
Read more →VERUAPP    ASPEN PARK PHARMACEUTICALS, INC. __________________________________________  F inancial S tatements  S eptember 30, 2016 and 2015     ASPEN P
ASPEN PARK PHARMACEUTICALS, INC. __________________________________________ Financial Statements September 30, 2016 and 2015 ASPEN PARK PHARMACEUTICAL, INC. ________________________________________ REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 1 FINANCIAL STATEMEN
Read more →VERUVeru Inc. Announces Agreement with Timm Medical Technologies, LLC to Distribute and to Promote PREBOOST
MIAMI, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), a biopharmaceutical company focused on urology and oncology, today announced it has signed a United States distribution and co-promotion agreement with Timm Medical Technologies for PREBOOST® (4% benzocaine wipes)
Read more →VERUVeru Inc. Announces Initiation of Telemedicine Capability to Expand Access to Prescriptions for FC2 Female Condom
MIAMI, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), (formerly, Nasdaq:FHCO) (”Veru” or the “company”), a biopharmaceutical company focused on urology and oncology, today announced the launch of its telemedicine capability to allow women and men better access to FC2
Read more →VERUVeru Inc. to Present at Two Financial Conferences in September
MIAMI, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), (formerly, Nasdaq:FHCO), a biopharmaceutical company focused on urology and oncology, today announces that it will participate in two upcoming financial conferences. Ladenburg Thalmann 2017 Healthcare Conference
Read more →VERUVeru Inc. (Nasdaq: VERU) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU), a biopharmaceutical company focused on urology and oncology, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Mitchell S. Steiner, M.D., F.A.C.S., President & CEO, will ring the Cl
Read more →VERUVeru Inc. to Participate in Upcoming Financial Conferences
MIAMI, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), a biopharmaceutical company focused on urology and oncology, today announces that it will participate in two upcoming financial conferences. Rodman & Renshaw’s 19
Read more →VERUVeru Inc. Announces Change in Nasdaq Ticker Symbol to VERU
MIAMI, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), formerly known as Veru Healthcare/The Female Health Company, a biopharmaceutical company focused on urology and oncology, today announced that as of August 7, 2017,
Read more →VERUxFEFF; Veru Inc. Reports Fiscal Third Quarter Financial Results   MIAMI –
Veru Inc. Reports Fiscal Third Quarter Financial Results MIAMI August 8, 2017 Veru Inc. (Nasdaq:VERU, formerly, Nasdaq:FHCO) ( Veru or the company ), formerly known as Veru Healthcare/The Female Health Company, a biopharmaceutical company focused on urology and oncology, today a
Read more →VERUVeru Inc. Reports Fiscal Third Quarter Financial Results
MIAMI, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), formerly known as Veru Healthcare/The Female Health Company, a biopharmaceutical company focused on urology and oncology, today announces financial results from its
Read more →VERUVeru Healthcare To Report Fiscal Third Quarter 2017 Financial Results and Corporate Performance on August 8, 2017
MIAMI, July 31, 2017 (GLOBE NEWSWIRE) -- Veru Healthcare (NASDAQ:FHCO), a biopharmaceutical company focused on urology and oncology, today announced that on August 8, 2017, the company will report financial results for its fiscal third quarter, which ended June 30, 2017. The com
Read more →VERUVeru Healthcare Announces Key Advancements in the Development of Tamsulosin DRS for Benign Prostatic Hyperplasia
MIAMI, July 20, 2017 (GLOBE NEWSWIRE) -- Veru Healthcare (NASDAQ:FHCO), a biopharmaceutical company focused on urology and oncology, today announced that the company has initiated the subject screening process for Stage 2 of its bioequivalence study of Tamsulosin DRS (Delayed Rel
Read more →VERUVeru Healthcare to Present at the 7th Annual LD Micro Invitational
MIAMI, June 02, 2017 (GLOBE NEWSWIRE) -- Veru Healthcare (NASDAQ:FHCO), a pharmaceuticals company focused on developing pharmaceuticals for men’s and women’s health and oncology, today announced that Mitchell Steiner, M.D., Chief Executive Officer, will present at the 7th Annual
Read more →VERUVeru Healthcare to Advance Proprietary Drug for the Treatment of Hot Flashes in Men Receiving Prostate Cancer Hormonal Therapy Following FDA Meeting
MIAMI, May 24, 2017 (GLOBE NEWSWIRE) -- Veru Healthcare (NASDAQ:FHCO), a pharmaceuticals company focused on developing pharmaceuticals for men’s and women’s health and oncology, today announced that following a Pre-Investigational New Drug Application meeting with the U.S. Food a
Read more →VERUFourth Amendment to Credit Agreement  This Fourth Amendment to Credit Agreement (herein, the “ Fourth Amendment ”) is effective as of March 3 0 , 2017 and entered into by and between THE FEMALE HEAL
This Fourth Amendment to Credit Agreement (herein, the Fourth Amendment ) is effective as of March 30, 2017 and entered into by and between THE FEMALE HEALTH COMPANY, a Wisconsin corporation ( FHC ), ASPEN PARK PHARMACEUTICALS, INC., a Delaware corporation ( APP ), BADGER ACQUISI
Read more →VERUVeru Healthcare Presents Results from Phase 4 Clinical Study of PREBOOST for Management of Premature Ejaculation
Analysis of men treated with PREBOOST® (topical 4% benzocaine wipes) showed statistically greater improvement in control of ejaculation, satisfaction with sexual intercourse, more pleasure and reduced frustration compared to placebo wipes After 2 months, men treated with PREBOOS
Read more →VERUVeru Healthcare Reports Fiscal 2017 Second-Quarter Financial Results
MIAMI, May 09, 2017 (GLOBE NEWSWIRE) -- Veru Healthcare (NASDAQ:FHCO) (the Company) today reported its financial results for the second fiscal quarter ended March 31, 2017. “We are excited about the great progress we have made in the past 5 months to execute our diversification
Read more →VERUKevin Gilbert: 312-366-2633 Veru Healthcare Reports Fiscal 2017 Second-Quarter Financial Results MIAMI
Veru Healthcare Reports Fiscal 2017 Second-Quarter Financial Results MIAMI May 9, 2017 Veru Healthcare (NASDAQ:FHCO) (the Company) today reported its financial results for the second fiscal quarter ended March 31, 2017. We are excited about the great progress we have made in t
Read more →VERUxFEFF;  Contact:  Kevin Gilbert 312-366-2633  The Female Health Company / Veru Healthcare Reports Fiscal 2016 Fourth-Quarter, Full-Year Financial Results  MIAMI –
Contact: Kevin Gilbert 312-366-2633 The Female Health Company / Veru Healthcare Reports Fiscal 2016 Fourth-Quarter, Full-Year Financial Results MIAMI December 12, 2016 The Female Health Company / Veru Healthcare (NASDAQ-CM: FHCO) (FHC or the Company) today reported its financ
Read more →VERUThe Female Health CompanyA Leading Men's and Women's Health and Oncology CompanyDecember 2016The Female Health Company/ Veru Healthcare NASDAQ: FHCOHeadquarters: Miami, FloridaOffices: Chicago, London, and Malaysia Forwa
The Female Health CompanyA Leading Men's and Women's Health and Oncology CompanyDecember 2016The Female Health Company/ Veru Healthcare NASDAQ: FHCOHeadquarters: Miami, FloridaOffices: Chicago, London, and Malaysia Forward Looking StatementsThis communication contains forward-lo
Read more →VERUxFEFF; Third Amendment to Credit Agreement  This Third Amendment to Credit Agreement (herein, the “ Third Amendment ”) is dated as of
This Third Amendment to Credit Agreement (herein, the Third Amendment ) is dated as of November 28, 2016 and entered into by and between THE FEMALE HEALTH COMPANY, a Wisconsin corporation ( FHC ), ASPEN PARK PHARMACEUTICALS, INC., a Delaware corporation ( APP ), BADGER ACQUISITIO
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fiscal 2016 Third Quarter and First Nine Months Operating Results --Record Date of
The Female Health Company Reports Fiscal 2016 Third Quarter and First Nine Months Operating Results --Record Date of July 28, 2016 Set for Special Meeting of Shareholders in Connection with Aspen Park Pharmaceuticals Merger-- Operating Results for Fiscal 2016 First Nine Months
Read more →VERUTranscript of Conference Call Edited Transcript The Female Health Company Third Quarter of FY2016 Operating Results Conference Call
Transcript of Conference Call The Female Health Company Third Quarter of FY2016 Operating Results Conference Call July 28, 2016 at 11:15 AM Eastern CORPORATE PARTICIPANTS O B Parrish President and Chief Executive Officer Good day, ladies and gentlemen, and welcome to The Femal
Read more →VERUWilliam R. Gargiulo, Jr. Michele Greco, CFO 231.526.1244 312.595.9123 THE FEMALE HEALTH COMPANY ANNOUNCES RECORD DATE FOR SPECIAL SHAREHOLDERS MEETING TO APPROVE MATTERS RELATING TO PROPOSED TRANSACTION WITH AS
THE FEMALE HEALTH COMPANY ANNOUNCES RECORD DATE FOR SPECIAL SHAREHOLDERS MEETING TO APPROVE MATTERS RELATING TO PROPOSED TRANSACTION WITH ASPEN PARK PHARMACEUTICALS CHICAGO (July 15, 2016) - The Female Health Company (FHC or the Company) (NASDAQ-CM: FHCO), manufacturer of the
Read more →VERUWilliam R. Gargiulo, Jr. Michele Greco, CFO 231.526.1244 312.595.9123 DRAFT #1 The Female Health Company to Present at the 2 nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday
The Female Health Company to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday, July 13, 2016 July 6, 2016 The Female Health Company (FHC) (NASDAQ-CM: FHCO), manufacturer of the world s leading female condom, the FC2, today announced that it will b
Read more →VERUThis communication contains forward-looking statements, including those regarding the proposed merger transaction between FHC and APP and the integration of our two businesses. These statements are subject to known and u
Veru Healthcare Proposed Merger of Aspen Park Pharmaceuticals & The Female Health Company Transforming into A Leading Men's and Women's Health Care Company June 2016 Abbreviated NASDAQ: FHCO Exhibit 99.1 This communication contains forward-looking statements, including those r
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 THE FEMALE HEALTH COMPANY TO PRESENT AT LD MICRO INVITATIONAL INVESTOR CONFERENCE ON TUESDAY, JUNE 7, 2016 CHICAGO (
THE FEMALE HEALTH COMPANY TO PRESENT AT LD MICRO INVITATIONAL INVESTOR CONFERENCE ON TUESDAY, JUNE 7, 2016 2016) The Female Health Company (FHC) (NASDAQ-CM: FHCO), manufacturer of the world s leading female condom, the FC2, today announced that it will be presenting at the LD
Read more →VERUFIRST AMENDMENT TO LOCK-UP AGREEMENT THIS FIRST AMENDMENT TO LOCK-UP AGREEMENT (this Amendment ), is made as of
FIRST AMENDMENT TO LOCK-UP AGREEMENT THIS FIRST AMENDMENT TO LOCK-UP AGREEMENT (this Amendment ), is made as of May 18, 2016, by and between THE FEMALE HEALTH COMPANY, a Wisconsin corporation ( FHC Wisconsin ), and the undersigned stockholder ( Stockholder ) of ASPEN PARK PHARM
Read more →VERUWilliam R. Gargiulo, Jr. Michele Greco, CFO 231.526.1244 312.595.9123 The Female Health Company to Present At the Drexel Hamilton Micro-Cap Investor Forum CHICAGO
The Female Health Company to Present At the Drexel Hamilton Micro-Cap Investor Forum CHICAGO May 5, 2016 The Female Health Company (NASDAQ-CM: FHCO) (FHC) today announced that the company will present at the Drexel Hamilton Micro-Cap Investor Forum on Thursday, May 12, 2016 at
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fiscal 2016 Second Quarter and First Half Operating Results Highlights for Fiscal 2016 First Half: Strateg
The Female Health Company Reports Fiscal 2016 Second Quarter and First Half Operating Results Highlights for Fiscal 2016 First Half: Objective Achievements CHICAGO (April 28, 2016) - The Female Health Company (NASDAQ:CM: FHCO) (the Company or FHC), which manufactures and mar
Read more →VERUTranscript of Conference Call Edited Transcript The Female Health Company Second Quarter of FY2016 Operating Results Conference Call
Transcript of Conference Call The Female Health Company Second Quarter of FY2016 Operating Results Conference Call April 28, 2016 at 11:15 a.m. Eastern CORPORATE PARTICIPANTS O.B. Parrish - Chief Executive Officer of The Female Health Company Mitch Steiner - Presiden
Read more →VERUMitchell Steiner, MD William R. Gargiulo, Jr. Michele Greco, CFO 901.581.5872 231.526.1244 312.595.9123 The Female Health Company and Aspen Park Pharmaceuticals to Discuss the Proposed Merger Conference Call Sc
The Female Health Company and Aspen Park Pharmaceuticals to Discuss the Proposed Merger Conference Call Scheduled Today Wednesday, April 13, 2016 at 11:00 a.m. ET CHICAGO (April 13, 2016) The Female Health Company (NASDAQ: FHCO) will host an investor conference call to discuss
Read more →VERUTranscript of Conference Call Edited Transcript The Female Health Company The Female Health Company and Aspen Park Pharmaceuticals to Discuss Proposed Merger
Transcript of Conference Call The Female Health Company The Female Health Company and Aspen Park Pharmaceuticals to Discuss Proposed Merger April 13, 2016 at 11:00 a.m. Eastern CORPORATE PARTICIPANTS O.B. Parrish - Chief Executive Officer, The Female Health Company Kevin G
Read more →VERUWilliam R. Gargiulo, Jr. Michele Greco, CFO 231.526.1244 312.595.9123 The Female Health Company and Aspen Park Pharmaceuticals to Discuss the Proposed Merger Conference Call Scheduled for Wednesday
The Female Health Company and Aspen Park Pharmaceuticals to Discuss the Proposed Merger Conference Call Scheduled for Wednesday, April 13, 2016 at 11:00 a.m. ET CHICAGO (April 7, 2016) The Female Health Company (NASDAQ: FHCO) today announced that it will host an investor confe
Read more →VERURobert Jaffe 424.288.4098 Mitchell Steiner, MD 901.581.5872 William R. Gargiulo, Jr. 231.526.1244 The Female Health Company Enters into Transformational Merger Agreement with Aspen Park Pharmaceuticals Proposed
Contacts: Robert Jaffe 424.288.4098 Mitchell Steiner, MD 901.581.5872 William R. Gargiulo, Jr. 231.526.1244 The Female Health Company Enters into Transformational Merger Agreement with Aspen Park Pharmaceuticals Proposed Merger Creates A Leading Men s and Women s Health and
Read more →VERUSEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE ("Agreement") is between The Female Health Company ("Company") and Susan Ostrowski ("Employee") effective
SEPARATION AGREEMENT THIS SEPARATION AGREEMENT AND GENERAL RELEASE ("Agreement") is between The Female Health Company ("Company") and Susan Ostrowski ("Employee") effective February 6, 2016 (the "Date of Agreement"). A. Employee's position with the Company is being eliminated.
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fiscal 2016 First Quarter Operating Results Highlights: - Unit sales increased 27% to 15.4 million from 12
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fiscal 2016 First Quarter Operating Results - Unit sales increased 27% to 15.4 million from 12.2 million in the prior-year period. - Net revenues increased 24% t
Read more →VERUEXECUTION VERSION Credit Agreement Dated as of December 29 , 2015 By and Between The Female Health Company (As the Borrower), And bmo harris bank n.a. (As the Bank) Table of Contents SECTION 1. DEFINITIONS; INTERPRETATIO
Dated as of December 29, 2015 The Female Health Company bmo harris bank n.a. SECTION 1. DEFINITIONS; INTERPRETATION. 1 Section 1.1 Definitions. 1 Section 1.2 Interpretation 14 Section 1.3 Change in Accounting Principles 15 SECTION 2. THE CREDIT FACILITIES. 15 Section 2.1 Reser
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fourth Quarter and Fiscal Year 2015 Operating Results 61 Million Units Sold in FY2015 Highlights FY2015: Y
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fourth Quarter and Fiscal Year 2015 Operating Results 61 Million Units Sold in FY2015 - Unit sales up 43% to 61.0 million. - Net revenues up 33% to $32.6 millio
Read more →VERUCHARTER 2 ex99-1oct62015form8k.htm ex99-1oct62015form8k.htm Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces 61 Million In Unit Sales for FY2015 Shipment
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces 61 Million In Unit Sales for FY2015 Shipments Rise 43% Compared to FY2014 Second Highest Unit Sales in Company History CHICAGO (October 6, 2015) - The Female
Read more →VERUCHARTER 2 ex99-1july2015firn8j.htm ex99-1july2015firn8j.htm Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Third Quarter and Nine-Month Operating Results
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Third Quarter and Nine-Month Operating Results - Unit sales totaled 14.4 million in third quarter and 47.3 million in first nine months of FY2015. -Net revenues
Read more →VERUCHARTER 2 ex-991toform8k.htm ex-991toform8k.htm SEPARATION AGREEMENT AND GENERAL RELEASE THIS SEPARATION AGREEMENT AND GENERAL RELEASE ("Agreement") is between The Female Health Company ("Company") and Karen King ("Emplo
SEPARATION AGREEMENT THIS SEPARATION AGREEMENT AND GENERAL RELEASE ("Agreement") is between The Female Health Company ("Company") and Karen King ("Employee") effective July 10, 2015 (the "Separation Date"). The Company and Employee desire to affect a final resolution and settle
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces 5% Increase in Third Quarter Unit Sales and Discusses Formation
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces 5% Increase in Third Quarter Unit Sales and Discusses Formation of Medical Advisory Board CHICAGO (July 1, 2015) - The Female Health Company (NASDAQ-CM: FHCO) t
Read more →VERUVerus Claims Services Names Matthew Urbanovich as Director of Business Development
LAWRENCEVILLE, NJ--(Marketwired - May 18, 2015) - Verus Claims Services, LLC, a leading administrator of mass tort cases, class-action settlements, and bankruptcy trusts, today announced the appointment of Matthew Urbanovich as Director of Business Development. In this newly crea
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Record Unit Sales for Second Quarter of FY2015 CHICAGO (
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Record Unit Sales for Second Quarter of FY2015 CHICAGO (April 2, 2015) - The Female Health Company (NASDAQ-CM: FHCO) today announced that it expects to report uni
Read more →VERUTO MARCH 19, 2015 FORM 8-K ex99-1tomarch1920158k.htm Contacts: W illiam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 Sharon Meckes Joins The Female Health Company Board of Directors CHICAGO (
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 Sharon Meckes Joins The Female Health Company CHICAGO (March 23, 2015) -- The Female Health Company (NASDAQ-CM: FHCO) (the "Company"), which manufactures and markets the FC2 Female Condom, today an
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports First Quarter FY2015 Operating Results First Quarter Highlights: - Unit sales of 12.2 million. - Net reven
The Female Health Company Reports First Quarter FY2015 Operating Results First Quarter Highlights: - Unit sales of 12.2 million. - Net revenues of $6.7 million. - Operating income of $1.5 million; operating margin of 22%. - Diluted EPS of $0.03. - Brazil orders 25 million
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fourth Quarter and FY2014 Operating Results FY2014 Highlights: - Company generates $3.7 million in cash fr
The Female Health Company Reports Fourth Quarter and FY2014 Operating Results - Company generates $3.7 million in cash from operations. - Unit sales of 42.5 million. - Net revenues of $24.5 million. - Operating income of $3.9 million; operating margin of 16%. - Diluted EPS of $
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Preliminary Unit Sales for Fourth Quarter 2014 CHICAGO, (
The Female Health Company Reports Preliminary Unit Sales for Fourth Quarter 2014 CHICAGO, (October 2, 2014) - The Female Health Company (NASDAQ-CM: FHCO) today announced preliminary unit sales for the fourth quarter of the fiscal year ended September 30, 2014 (FY2014). The Com
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations CHICAGO, (
The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations CHICAGO, (September 15, 2014) - The Female Health Company (NASDAQ-CM: FHCO), today announced that Martin Tayler will join the Company's management team as Executive Vice President of
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Third Quarter Operating Results Highlights: - Third quarter fiscal year 2014 unit sales total 13.7 million
The Female Health Company Reports Third Quarter Operating Results - Third quarter fiscal year 2014 unit sales total 13.7 million, a 9% increase when compared with prior year quarter. - Operating income increases 86% to $2.0 million in most recent quarter compared to the prior
Read more →VERUTO FORM 8-K ex991toform8k.htm Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces Major New Strategic Direction and Dividend Decision Company to Report High
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Announces Major New Strategic Direction and Dividend Decision Company to Report Higher Unit Sales For Third Quarter of FY2014 CHICAGO, July 14, 2014 - The Female Healt
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Second Quarter Operating Results Highlights: - Unit sales, 7.3 million in the Second Quarter; 19.1 million
The Female Health Company Reports Second Quarter Operating Results - Unit sales, 7.3 million in the Second Quarter; 19.1 million in First Half of FY2014 - Net revenues, $4.3 million in the Second Quarter; $11.0 million in First Half of FY2014 - Operating income, $2.4 million
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares Second Quarter Dividend CHICAGO (
The Female Health Company Declares Second Quarter Dividend CHICAGO (March 24, 2014) - The Female Health Company (NASDAQ-CM: FHCO), today announced that its Board of Directors has declared a quarterly cash dividend of $0.07 per share. This represents the Company's 18th consecutiv
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports First Quarter Operating Results First Quarter: - Company generates $1.2 million in cash from operations -
The Female Health Company Reports First Quarter Operating Results - Company generates $1.2 million in cash from operations - Unit sales of 11.8 million units - Net revenues of $6.7 million - Operating income of $1.6 million - Diluted EPS of $0.05 - Operating margin of 24% - Cas
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares First Quarter Dividend and Extends Stock Repurchase Program CHICAGO (
The Female Health Company Declares First Quarter Dividend and Extends Stock Repurchase Program CHICAGO (December 16, 2013) - The Female Health Company (NASDAQ-CM: FHCO), today announced that its Board of Directors has declared a quarterly cash dividend of $0.07 per share. This
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Names Karen King President and Chief Executive Officer CHICAGO (
The Female Health Company Names Karen King President and Chief Executive Officer CHICAGO (December 11, 2013) - Today The Female Health Company (NASDAQ-CM: FHCO), announced that Karen King will become President and CEO effective January 20, 2014. O.B. Parrish, a Company founder
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Fourth Quarter and FY2013 Operating Results FY2013 Highlights: - Company generates $11.8 million in cash
The Female Health Company Reports Fourth Quarter and FY2013 Operating Results - Company generates $11.8 million in cash from operations - Unit sales of 54.8 million units, 11% less than FY2012 - Net revenues of $31.5 million - Operating income of $9.8 million - Diluted EPS
Read more →VERUW illiam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares Fourth Quarter Cash Dividend of $0.07 Per Share CHICAGO (
The Female Health Company Declares Fourth Quarter Cash Dividend of $0.07 Per Share CHICAGO (October 4, 2013) - The Female Health Company (NASDAQ-CM: FHCO), today announced that its Board of Directors has declared a quarterly cash dividend of $0.07 per share. This represents the
Read more →VERUW illiam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 Michael Walton Retires From The Female Health Company Board of Directors CHICAGO
Michael Walton Retires From The Female Health Company CHICAGO, September 10, 2013 - The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC2 Female Condom, today announced that Michael R. Walton retired from its Board of Directors effective Sep
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Third Quarter and Nine-Month FY2013 Operating Results Nine-Month Highlights: Company generates $12.8 milli
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Reports Third Quarter and Nine-Month FY2013 Operating Results Nine-Month Highlights: Company generates $12.8 million in cash from operations in first nine months of
Read more →VERUTO FORM 8-K ex991toform8k.htm Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Expects Lower Unit Shipments in Third Fiscal Quarter vs. Prior-Year Period Board of
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Expects Lower Unit Shipments in Third Fiscal Quarter vs. Prior-Year Period Board of Directors Declares Third Quarter Cash Dividend of $0.07 per Common Share CHICAGO,
Read more →VERUW illiam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 Andrew Love Joins The Female Health Company Board of Directors CHICAGO
The Female Health Company CHICAGO, May 14, 2013 - The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC2 Female Condom, today announced that it has named Andrew S. Love to be a member of its Board of Directors. Mr. Love is Chairman of Love Sa
Read more →VERUWilliam R. Gargiulo, Jr. Michele Greco 231.526.1244 312.595.9123 The Female Health Company Reports 21% Rise in Net Revenues and 55% Increase in Operating Income for Second Quarter of FY2013 Diluted E.P.S. Incre
The Female Health Company Reports 21% Rise in Net Revenues and 55% Increase in Operating Income for Second Quarter of FY2013 Diluted E.P.S. Increase 71% to $0.12, Versus $0.07 in Prior-Year Quarter Second Quarter Results: Unit sales increase 20% to 16.7 million units Net rev
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares Second Quarter Cash Dividend at 17% Higher Payout Rate Company Also Plans to Increa
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares Second Quarter Cash Dividend at 17% Higher Payout Rate Company Also Plans to Increase Activity under Stock Repurchase Program CHICAGO, March 27, 2013 - The Fema
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco 312.595.9123 The Female Health Company Reports Record First Quarter FY2013 Operating Results Diluted E.P.S. Increase 33% to $0.12, Versus $0.09 in Prior-Year
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco 312.595.9123 The Female Health Company Reports Record First Quarter FY2013 Operating Results Diluted E.P.S. Increase 33% to $0.12, Versus $0.09 in Prior-Year Quarter Selected Highlights: Unit sales increa
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares First Quarter Dividend and Extends Stock Repurchase Program CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Michele Greco, CFO 312.595.9123 The Female Health Company Declares First Quarter Dividend and Extends Stock Repurchase Program CHICAGO, January 3, 2013 - The Female Health Company (NASDAQ-CM: FHCO - News) today announced that it
Read more →VERUCONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this "Agreement") is entered into as of
CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this "Agreement") is entered into as of January 1, 2013 (the "Effective Date"), between THE FEMALE HEALTH COMPANY, a Wisconsin corporation (the "Company"), and DONNA FELCH ("Ms. Felch"). A. Ms. Felch retired as Vice President and
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results FY2012 Diluted EPS Rise 179% to $0.53 vs. $0.19 in FY2011 Sele
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results FY2012 Diluted EPS Rise 179% to $0.53 vs. $0.19 in FY2011 Selected Highlights: Fourth Quarter Results: Unit s
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Announces Pending Retirement of CFO Donna Felch Michele Greco to Assume CFO Position on
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Announces Pending Retirement Michele Greco to Assume CFO Position on January 1, 2013 CHICAGO, Illinois November 9, 2012- The Female Health Company (NASDAQ-CM: FHCO - News), whic
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4th Quarter Dividend CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4th Quarter Dividend CHICAGO, October 5, 2012 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors has declared a qu
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Third Quarter Operating Results Operating Income Rises 523% On 146% Revenue Increase Selected Highlights : Third
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Third Quarter Operating Results Operating Income Rises 523% On 146% Revenue Increase Selected Highlights: Third Quarter Results: Unit sales: 157% increase Net
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 3rd Quarter Dividend CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 3rd Quarter Dividend CHICAGO, July 13, 2012 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors has declared a quarte
Read more →VERUW illiam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Second Quarter Operating Results Operating Income Rises 20-Fold On 83% Revenue Increase Selected Highlights: Sec
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Second Quarter Operating Results Operating Income Rises 20-Fold On 83% Revenue Increase Selected Highlights: Second Quarter Results: Units: increase 57% Revenues
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares Second Quarter Cash Dividend Company Increases Quarterly Payout By 20% to $0.06 per S
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares Second Quarter Cash Dividend Company Increases Quarterly Payout By 20% to $0.06 per Share CHICAGO, March 27, 2012 - The Female Health Company (NASDAQ-CM: FHCO -
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports First Quarter Operating Results Unit sales and Revenue hit new records Operating Income Ris
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports First Quarter Operating Results Unit sales and Revenue hit new records Operating Income Rises 541% On 136% Revenue Increase FY 2012 First Quarter Highlights: Unit
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 1st Quarter Dividend of $0.05/share and Extends its Stock Repurchase Program CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 1st Quarter Dividend of $0.05/share and Extends its Stock CHICAGO, January 5, 2012 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its B
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Fiscal Year 2011 Results Fourth Quarter Operating Income Exceeds Operating Income During Fi
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Fiscal Year 2011 Results Fourth Quarter Operating Income Exceeds Operating Income During First Nine Months of Fiscal Year by 134% Gross margin improves to 59.5% vs. 4
Read more →VERUTO FEMALE HEALTH COMPANT FORM 8-K ex991tofhcoform8k.htm For Immediate Release Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4 th Quarter Dividend of $0.0
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4th Quarter Dividend of $0.05/share. CHICAGO, October 7, 2011 - The Female Health Company (NASDAQ-CM: FHCO), today announced that its Board of Directors has declar
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Third Quarter Operating Results Highlights: Company generates $4.6 million in cash fro
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Third Quarter Operating Results Company generates $4.6 million in cash from operations in first nine months of FY2011 Revenues increase 101% over the same perio
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Expects to Report Modest Profit in FY2011 Third Quarter despite Continued Delays in Receipt an
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Expects to Report Modest Profit in FY2011 Third Quarter despite Continued Delays in Receipt and Shipping of Large Orders Board of Directors Declares Third Quarter Cash Div
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Second Quarter Operating Results and Confirms Annual Guidance Highlights: Brazil cont
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Second Quarter Operating Results and Confirms Annual Guidance Brazil contract for up to 20 M units of FC2 awarded to Semina Ind stria e Com rcio, FHCO's exclusi
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 2nd Quarter Dividend of $0.05/share CHICAGO
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 2nd Quarter Dividend of $0.05/share CHICAGO, April 13, 2011 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors has
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports First Quarter Operating Results and Reaffirms Annual Guidance Highlights: Gross Margin approximates 55.2% o
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports First Quarter Operating Results and Reaffirms Annual Guidance Gross Margin approximates 55.2% of net revenues Operating Profit of $0.4 million Pretax Margin
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 1st Quarter Dividend of $0.05/share CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 1st Quarter Dividend of $0.05/share CHICAGO, January 14, 2011 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors has
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Fiscal Year 2010 Results Fourth Quarter Operating Income Hits New Record Highlights: Fourt
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Fiscal Year 2010 Results Fourth Quarter Operating Income Hits New Record Records - Unit sales rise 19% to 13.8 million - Gross margin 59.0% vs. 48.5% in prior-year
Read more →VERUTO FHCO FORM 8-K 10/8/2010 ex991fhco8k1082010.htm For Immediate Release Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4th Quarter Dividend of $0.05/share
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 4th Quarter Dividend of $0.05/share. CHICAGO, October 8, 2010 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors h
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Third Quarter Operating Results and Updates Annual Guidance Highlights: Company recor
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Third Quarter Operating Results and Updates Annual Company records net income of $75,159 for Q3 of FY2010 Due to delay in two large pending orders, unit sales
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Anticipates Lower Sales and Modest Loss in FY2010 Third Quarter Due to Timing and Shipment of
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Anticipates Lower Sales and Modest Loss in FY2010 Third Quarter Due to Timing and Shipment of Large Orders Board of Directors Declares Third Quarter Cash Dividend of $0.
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Second Quarter Operating Results and Confirms Annual Guidance Company to Pay Quarterly
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports Second Quarter Operating Results and Confirms Annual Company to Pay Quarterly Cash Dividend of $0.05 Per Share in May 2010 Unit sales up 26%, Net Revenues decrea
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 2nd Quarter Dividend of $0.05/share. CHICAGO
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Declares 2nd Quarter Dividend of $0.05/share. CHICAGO, April 12, 2010 - The Female Health Company (NASDAQ-CM: FHCO - News), today announced that its Board of Directors has
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports First Quarter Operating Results and Confirms Annual Guidance Highlights: FHC records $
R. Gargiulo, Jr. 231.526.1244 Female Health Company First Quarter Operating Results and Confirms Annual FHC records $1.9 M restructuring charge reflecting final transition from FC1 to FC2 Unit sales up 20%, Net Revenues up 3%, reflecting transition to FC2 Gross Margin ri
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Initiates Cash Dividend Policy Company Reiterates FY2010 Unit Sales and Earnings Guidance CHICAGO
Female Health Company Initiates Cash Dividend Policy Reiterates FY2010 Unit Sales and Earnings Guidance January 19, 2010 - The Female Health Company (NASDAQ-CM: FHCO - News) today announced that its Board of Directors has declared a quarterly cash dividend of $0.05 per share.
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Record Profit for Fiscal Year 2009 Excluding Restructuring Costs for Each, Operating Incom
Contacts : William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 Female Health Company Reports Record Profit for Restructuring Costs for Each, Operating Income Exceeds Previous Earnings Completes FC1 to FC2 Transition Payment of Dividend in Calendar 2010 FHC reco
Read more →VERUDATED 2nd November 2009 O&T PROPERTIES LIMITED (1) and THE FEMALE HEALTH COMPANY (UK) PLC (2) and THE FEMALE HEALTH COMPANY (3) LEASE in respect of part of Unit 1, Sovereign Park, Coronation Road, London NW10 7QP Manches
O&T PROPERTIES LIMITED THE FEMALE HEALTH COMPANY (UK) THE FEMALE HEALTH COMPANY Sovereign Park, Coronation Road, London NW10 7QP SPS/ELV/181966/259021 All words in italicised text and inapplicable alternative wording in a clause may be omitted or deleted. Clause LR13 may b
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Completes 150% Expansion of FC2 Manufacturing Capacity in Malaysia Confirms Earnings Guidance for
Female Health Company Completes 150% Expansion of FC2 Manufacturing Capacity in Earnings Guidance for FY 2009 October 21, 2009- The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC Female Condom (FC1) and FC2 Female Condom reported that i
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports 23% Increase in Third Quarter Revenues Operating Income Rises 275% to $1.5 Million Increas
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports 23% Increase in Third Quarter Revenues Operating Income Rises 275% to $1.5 Million Increases Earnings Guidance Third quarter highlights: 275% Operating Profit incre
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports 67% Increase in Second Quarter Earnings Operating Income Rises 172% to Record $2.3 Million
172% Operating Profit Increase to $2.3 Million Gross Profit Margin widens to 53% of net revenues vs. 42% in prior year quarter 46% Gross Profit Increase E.P.S. of $0.07 vs. $0.04 in prior-year quarter Year-to-date highlights: Gross Margin widens to 50% of net revenue vs
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports First Quarter Operating Results, as Gross Profit Margins Widen on Increasing Sales of
Female Health Company First Quarter Operating Results, as Gross Profit Margins Widen on Increasing Sales of FC2 Female Condom Reaffirms Guidance Anticipating Record FY2009 Illinois -- February 10, 2009 -- The Female Health Company (NYSE Alternext: which manufactures and mark
Read more →VERUEXBIBIT 99.1 TO FHC DEC 1, 2008 FORM 8-K ex991tofhcdec12008form8k.htm For Immediate Release Contacts : William R. Gargiulo, Jr. 3 12-526-1244 Donna Felch, CFO 312-595-9123 THE FEMALE HEALTH COMPANY REPORTS RECORD RESULTS
FEMALE HEALTH COMPANY REPORTS RECORD RESULTS FOR FISCAL YEAR 2008, AT HIGH INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS RISES 215% TO $4.8 MILLION ($0.18 December 1, 2008- The Female Health Company (AMEX: FHC which manufactures and markets the FC Female Condom , today reported
Read more →VERU: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Confirms Guidance for FY Ended
Female Health Company Confirms Guidance for FY November 6, 2008- The Female Health Company (AMEX: FHC which manufactures and markets the FC and FC2 Female Condoms , today confirmed its guidance for the fiscal year ended September 30, very pleased to confirm that our August
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports 60% Increase in Third Quarter Earnings Company Increases Full-Year Earnings Guidance; Preta
For Immediate Release Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 Female Health Company Reports 60% Increase in Third Quarter Increases Full-Year Earnings Guidance; Pretax Income Expected to Rise 200%-250% August 12, 2008- The Female Health Compan
Read more →VERUTO MAY 14, 2008 FORM 8-K ex99-1tomay142008form8k.htm For Immediate Release Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports 267% Increase in Second Quarter Earnin
Female Health Company Reports 267% Increase in E.P.S. of $0.07 in First Half of FY2008 May 14, 2008- The Female Health Company (AMEX: FHC which manufactures and markets the FC and FC2 Female Condoms , today reported its operating results for the second quarter and first half
Read more →VERUWilliam R. Gargiulo, Jr 231.526.1244 Donna Felch 312.595.9742 The Female Health Company Doubles its Stock Repurchase Program and Gives Financial Guidance for FY 2008 CHICAGO, Illinois - (
Contacts: William R. Gargiulo, Jr 231.526.1244 Donna Felch 312.595.9742 Female Health Company Doubles its Stock Repurchase Program and Gives Financial Guidance for FY 2008 Illinois - (April 3, 2008) - The Female Health Company (AMEX: FHC) announced today that the program in
Read more →VERUTHE FEMALE HEALTH COMPANY 2008 STOCK INCENTIVE PLAN (Effective as of
FEMALE HEALTH COMPANY STOCK INCENTIVE PLAN as of March 27, 2008) Purposes of the Plan. The purpose of this Plan is to advance the interests of the Company's shareholders by enhancing the Company's ability to attract, retain and motivate persons make (or are expected to make
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch, CFO 312.595.9123 The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008 First Quarter Highlights: 37% Revenue Incr
Gargiulo, Jr. 231.526.1244 Female Health Company 37% Revenue Growth and Record Profits for February 13, 2008- The Female Health Company (AMEX: FHC which manufactures and markets the FC and FC2 Female Condoms , today reported its operating results for the first quarter of FY
Read more →VERUWilliam R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007 Highlights : 4 th Qtr. Revenue I
Contacts: William R. Gargiulo, Jr. 231.526.1244 Donna Felch 312.595.9123 Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal November 26, 2007- The Female Health Company (AMEX: FHC - News), which manufactures and markets the FC Female Condom , today
Read more →VERUVerus Launches Online Patient Accounts Center for Freeman Health System
SEATTLE, June 23, 2005 (PRIMEZONE) -- Verus announces the launch of the online Verus Patient Account Center (vPAC) at Freeman Health System in Joplin, MO. vPAC is an online patient billing application that streamlines the hospital billing process; resulting in faster collection
Read more →Competitive Position
How VERU ranks across every disease it competes inCompetitive Position is a premium feature
See how VERU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial